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1. INTRODUCTION 
 
1.1 Parkinson’s disease 
Parkinson's disease (PD) is the second most common human neurodegenerative disorder, 
after Alzheimer's dementia. This disease is progressive, with a mean age at onset of 60, 
and its incidence increases markedly with age 1. 
Clinically, most patients present with a motor disorder and suffer from slowness of 
movement, rest tremor, rigidity, and disturbances in balance. A number of patients also 
suffer from anxiety, depression, autonomic disturbances, and dementia 2. Additional 
common symptoms included sleep difficulties, loss of sense of smell, constipation, speech 
and swallowing problems, unexplained pains, drooling, constipation, and low blood 
pressure when standing. 
Parkinson's symptoms manifest differently in different patients and the pace at what the 
disease worsens varies on an individual basis. 
Typically, symptoms begin on one side of the body and migrate over time to the other side. 
There is no test (such as a blood test, brain scan or EEG) to make a diagnosis of PD. 
Frequently, the doctor will also look for responsiveness to Parkinson's medications as 
further evidence that Parkinson's is the correct diagnosis. 
 
PD was first described in the Western world in 1817 by James Parkinson, a British 
physician who published an essay on what he called "the shaking palsy".  
The biochemical changes underlying the disease were elucidated in the 1950s: the 
discovery of dopamine as a neurotransmitter in the brain by Arvid Carlsson, and the 
subsequent insight provided by Paul Greengard into the cellular signalling mechanisms 
triggered by dopamine, gained these researchers the Nobel Prize for Medicine in 2000.  
 
The discovery of dopamine was followed very quickly by reports of markedly depleted 
levels of dopamine in the basal ganglia of individuals with PD. 
The main PD pathological hallmarks are the preferential loss of dopaminergic neurons of 
the substantia nigra pars compacta (SNpc) and formation of Lewy bodies — 
intracytoplasmic inclusion bodies that are mainly composed of fibrillar a-synuclein 
(SNCA). 
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Clinical symptoms of PD arise by a threshold effect, whereby denervation of the corpus 
striatum by dopaminergic neuronal loss reduces dopamine levels to below 70% of wild 
type 3. 
 
1.1.1 Neuropathological features  
The pathologic examination of brains from PD patients demonstrates depigmentation of 
the substantia nigra (SN), caused by the selective and progressive loss of dopaminergic 
neurons projecting in the striatum. Importantly, approximately 60-80% of dopaminergic 
neurons are lost before the motor signs of PD emerge. Depletion of dopamine within the 
striatum causes dysregulation of the motor circuits that project throughout the basal 
ganglia, resulting in the clinical manifestations of PD. 
 
Dysregulation of the motor circuits 
The severity of dopamine depletion and the consequent pathophysiologic changes that 
occur in basal ganglia circuits determine the severity of parkinsonian signs. Restoring the 
dopamine deficit or the downstream physiologic abnormalities improves Parkinson’s 
Disease (PD) main motor features. Therefore, both the magnitude and duration of the 
motor response are a function of the degree of motor severity, which is primarily governed 
by the loss of tonic dopaminergic activity and disruption of basal ganglia homeostatic 
mechanisms 4. 
The basal ganglia motor circuit modulates cortical output necessary for normal movement: 
signals from the cerebral cortex are processed through the basal ganglia-thalamocortical 
motor circuit and return to the same area via a feedback pathway. The basal ganglia are 
composed of four principal nuclei: the striatum, the globus pallidus (GP) consisting of 
external and internal segments (GPi and GPe), the substantia nigra (SN) consisting of pars 
compacta and reticulata (SNc and SNr), and the subthalamic nucleus (STN).  The striatum 
is the major recipient of input to the basal ganglia from the cerebral cortex, thalamus and 
brainstem. Its neurons project to the GP and SNr. The output nuclei of the basal ganglia are 
GPi and SNr. Their inhibitory output is directed to the thalamocortical pathway and 
suppresses movement.  
 
SN dopaminergic neurons project to ipsilatral striatum (caudate nucleus and putamen). 
Dopamine release from SN neurons stimulates D1 receptors and inhibits D2 receptors, 
resulting in the striatum sending impulses to the motor cortex (called the basal ganglia-
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thalamocortical motor circuit) in a direct excitatory pathway via thalamic nuclei. 
Concomitant inhibitory impulses to the motor cortex in a polysynaptic indirect pathway are 
sent via globus pallidus externa, subthalamic nucleus, and thalamic nuclei are also sent. 
Loss of dopaminergic nigral cells leads to striatal dopamine depletion and overall 
decreased motor cortex excitation. The loss of excitatory stimulation decreases excitatory 
activity of the direct pathway to the motor cortex and increases inhibitory activity of the 
indirect pathway. Not yet completely understood, the increased inhibitory input to the 
motor cortex causes bradykinesia 5. 
 
Figure 1. Basal ganglia circuitry in normal conditions (left) and in Parkinson’s disease (right). Adapted 
from: Expert Reviews in Molecular Medicine C 2003 Cambridge University Press.  
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Lewy Bodies 
Brains from PD patients are indeed characterized by the presence of intraneuronal 
proteinaceous inclusions known as Lewy bodies within the surviving neurons of the SN 
and other brain regions (dorsal motor nucleus of the vagus, locus coeruleus, raphe and 
reticular formation nuclei, thalamus, amygdala, olfactory nuclei, pediculopontine nucleus, 
and cerebral cortex, among others). These inclusions are enriched in filamentous SNCA 
and other proteins.  
 
 
Figure 2. Substantia nigra from patients with Parkinson’s disease (from the MRC Cambridge Brain Bank) 
immunostained for SNCA. a, Two pigmented nerve cells, each containing an SNCA positive Lewy body 
(thin arrows). Lewy neurites (thick arrows) are also immunopositive. Scale bar, 20 mm. b, A pigmented 
nerve cell with two SNCA-positive Lewy bodies. Scale bar, 8 mm. c, SNCA positive, extracellular Lewy 
body. Scale bar, 4 mm.  
 
Lewy body (LB) pathology evolves in six consecutive stages affecting multiple neuronal 
systems. Lesions initially occur in the medulla oblongata, namely the dorsal motor nucleus 
of the glossopharyngeal and vagal nerves, and in the anterior olfactory nucleus (stage 1). In 
stage 2, monoaminergic nuclei of the brainstem (raphe nuclei, locus coeruleus) are 
involved, whereas the SN becomes affected only at stage 3. In subsequent stages, the 
pathological alterations take an ascending course with increasing involvement of the 
cerebral cortex, beginning with the anteromedial temporal mesocortex followed by 
neocortical areas 6. 
The novel neuropathological findings characterizing PD as a multisystemic disorder 
starting in the medulla oblongata and the anterior olfactory nucleus correspond to the 
recognition that non-motor symptoms are a frequent, if not inevitable, feature of PD. Most 
remarkably, early symptoms of PD are typically non-motor, implying that parkinsonism is 
not the first manifestation of PD. The neuropathological alterations outside the SN are well 
correlated with the non-motor symptoms of PD. The findings of abnormal olfactory 
  8 
function in early stages of PD correspond to the neuropathological observation that the 
occurrence of Lewy bodies in the anterior olfactory nucleus is an early feature of the PD . 
 
 
Fig. 3 – Progression of PD-related intraneuronal pathology7. 
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1.1.2 Pathogenesis 
The exact cause of PD is unknown, although research points to a combination of genetic 
and environmental factors. 
PD is generally a sporadic disorder, but in a significant proportion of cases (10–15% in 
most studies) it segregates as a Mendelian trait with either autosomal dominant or 
recessive inheritance. The common form of PD is therefore likely to be a complex trait, 
determined by several genetic as well as non-genetic factors.  
Age of onset tends to be younger in familial PD compared with sporadic PD, particularly 
so in autosomal recessive PD.  
In the last few years family-based linkage analysis and positional cloning have led to the 
identification of several loci and genes for the rare monogenic forms and more recently of 
two loci for the classical, non-Mendelian forms (Tab.1).  
 
  
Tab. 1 – Loci, genes and susceptibility factors involved in parkinsonism 8. 
 
Although the monogenic forms account for a very small fraction of PD patients, they are 
promoting the understanding of the molecular pathways in sporadic cases. Even if older 
age and neurotoxins are established risk factors, several causative genes and susceptibility 
factors have been identified in rare families with Mendelian inheritance, and suggest that 
abnormal handling of misfolded proteins by the ubiquitin-proteasome and autophagy-
lysosomal systems, mitochondrial dysfunctions and increased oxidative stress, and other 
pathogenic dysfunctions, contribute to PD 8. 
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Misfolded proteins 
Normal balance between the formation and degradation of cellular proteins is required for 
cell survival. The pathways by which most cytosolic and misfolded proteins are degraded 
are carried out by ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway 
(ALP) 9,10. Impairment of either of these systems may lead to the accumulation and 
aggregation of proteins. Misfolded accumulated proteins are present in specific populations 
of neurons and in brain areas physiologically linked to the observed clinical 
manifestations. Each neurodegenerative disorder has a unique histopathological signature 
defined by the constituent protein and the distribution and cellular localization of the 
deposits. The contribution of these aggregated proteins to neuronal death has been debated; 
for example it has been proposed that the nuclear deposition of huntingtin in Huntington’s 
disease may be neuroprotective, while soluble oligomeric forms of the amyloid β peptide 
found in senile plaques in Alzheimer’s disease are thought to be the primary cytotoxic 
species in the disease11. 
Increased oxidative stress, associated with depletion of ATP, is considered to contribute to 
the reduction of proteasome activity and aggregation of abnormal proteins 12,13,14,15.  
UPS 
The UPS is responsible for a highly selective degradation of short-lived intracellular and 
plasma membrane proteins under basal metabolic conditions, as well as misfolded or 
damaged proteins in the cytosol, nucleus or endoplasmic reticulum. The system involves 
the targeting of susceptible proteins by ubiquitin and only the unfolded ubiquitinated 
proteins can pass through the narrow pore of the proteasome barrel. 
PD and other synucleinopathies (Dementia with Lewy Bodies, Multisystem Atrophy) are 
characterized by the accumulation of filamentous aggregates of SNCA in Lewy bodies, 
which co-stain with ubiquitin, pointing to a role of the ubiquitin-proteasome system in the 
disease. Selective loss of the 20S subunit and of the functional activity of the proteosome 
is also evident in PD post mortem brains. Beside SNCA, other genes involved in the 
familiar cases are closely linked to the degradation system. The ubiquitin carboxyl-
terminal esterase L1 (UCH-L1) gene encodes an ubiquitin hydrolase and ligase, it is 
mutated in rare familial cases of PD and the protein is found in Lewy bodies of sporadic 
PD. Parkin, the most common cause of familial cases of PD, appears to function as an 
ubiquitin E3 ligase.  Parkin is a 465 amino acid protein containing two RING fingers 
separated by an in-between RING (IBR) domain at the carboxyl terminus. The amino 
terminal bears a ubiquitin-like domain that binds to the RPN10 subunit of the 26S 
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proteasome. It has been proposed that parkin dysfunction might lead to the toxic 
accumulation of its substrate. Many substrates for parkin have been discovered, among 
which the septins CDCREL1 and PAEL-R 16. Over-expression of CDCREL1 and PAEL-R 
in vivo mediates dopaminergic neurodegeneration 17,18, and both also accumulate in the 
brains of patients with parkin-related autosomal recessive Parkinson’s disease (ARPD) 
19,20, but not in Drosophila or mammalian parkin knockout models. By contrast, the parkin 
substrate aminoacyl-tRNA synthetase cofactor p38 is upregulated in the midbrain of parkin 
null mice as well as in the brains of patients with ARPD and idiopathic PD and its 
adenovirus-mediated overexpression in the substantia nigra of mice induces loss of 
dopaminergic neurons 21. Interestingly, it has been observed that parkin can rescue neurons 
from SNCA-induced proteasomal dysfunction 22. Moreover, mutations of ATP13A2 that 
encodes for a lysosomal ATPase 23,24 have also been shown to result in impaired protein 
degradation.  
 
ALP 
The ALP can be divided into three distinct pathways based on the ways substrates reach 
the lysosomal lumen: macroautophagy (generally referred to as autophagy), 
microautophagy and chaperone-mediated autophagy (CMA) 25,26. Autophagy can be 
induced within short periods of nutrient deprivation, and CMA can be induced after 
prolonged nutrient deprivation, while microautophagy is not activated by nutritional 
deprivation or stress. In contrast to the UPS, the major inducible autophagy is likely to be 
the primary mechanism involved in the degradation of long-lived, stable proteins and is the 
only mechanism by which entire organelles such as mitochondria are recycled. Large 
membrane proteins and protein complexes (including oligomers and aggregates) that fail to 
pass through the narrow proteasome barrel can be degraded by autophagy 27,25,26,28. 
In addition to the UPS, SNCA is also cleared by autophagy 29,25,30,31, which supports the 
hypothesis that impaired autophagic degradation of SNCA is an important mechanism of 
neurodegeneration in Parkinson's disease 25. Indeed, lysosomal malfunction accompanies 
SNCA aggregation in a progressive mouse model 32, and mutations in ATP13A2, a 
lysosomal ATPase, lead to a failure of autophagy execution and aggregation of SNCA in 
Parkinson's disease 23,24 further supporting the hypothesis that ALP dysfunction is an 
important mechanism of neurodegeneration. 
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Mitochondrial dysfunctions and oxidative stress 
Mitochondrial dysfunction 
Mitochondrial dysfunction has long been implicated in the pathogenesis of PD. An 
important feature of the PD post mortem brains is a reduction of mitochondrial complex I 
activity, discovered in 1983 when the accidental exposure of drug abusers to 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) resulted in acute and irreversible parkinsonian 
syndromes 33. MPTP inhibits the first enzymatic complex of the mithochondrial electron-
transfer chain. After systemic administration, it crosses the blood brain barrier in minutes 
and, once in the brain, is oxidized to MPDP+ by monoamine oxidase B (MAO-B) in glia 
and serotoninergic neurons. It is then converted to the active toxic molecule MPP+, likely 
by spontaneous oxidation. MPP+ is a high affinity substrate for the dopamine transporter 
DAT and for norepinephrine and serotonin transporters. It then accumulates in 
dopaminergic neurons, where it confers toxicity and cell death through complex I 
inhibition and the resulting energy crisis and generation of free radicals. Furthermore, 
other environmental neurotoxins and inhibitors of complex I such as rotenone and paraquat 
are also able to induce dopaminergic loss. Rats administered with rotenone develop a PD-
like syndrome characterized by neuronal degeneration and the formation of SNCA-rich 
inclusion bodies. Recently, strong evidences supporting the role of mithochondrial 
dysfunction in PD came from the discovery of some familial genes: although SNCA and 
parkin mutations confirm that protein misfolding and UPS dysfunction play a major role in 
dopaminergic degeneration, these genes seem to be also implicated in mitochondrial 
dysfunction. The discovery of HtrA serine peptidase 2 (Omi/HtrA2), PINK1 and DJ-1 
mutations confirmed that mitochondrial dysfunction is a main upstream pathway to 
parkinsonism.   
 
SNCA has been found to interact with cytochrome C oxidase (complex IV), the last protein 
in the mitochondrial electron transport chain, in a yeast two hybrid screening 34. In 
transgenic mice, over-expression of SNCA impairs mitochondrial function, increases 
oxidative stress and enhances nigral pathology induced by MPTP 35. Moreover, in mice 
over-expressing A53T SNCA, degenerating mitochondria were found to be immunostained 
for SNCA, raising the possibility that mutant SNCA might damage mitochondria directly 
36. Whereas over-expression of SNCA increases sensitivity to MPTP, SNCA null mice are 
resistant to MPTP 37 as well as to other mitochondrial toxins such as malonate and 3-
nitropropionic acid 38. Thus, SNCA seems to mediate some of the toxic effects of MPTP.  
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Parkin deficiency or mutations have been shown to lead to mitochondrial dysfunction and 
oxidative stress. Leukocytes from individuals with Parkin mutations present a selective 
impairment in complex-I activity 39. Parkin can associate with the outer mitochondrial 
membrane and prevent mitochondrial swelling, cytochrome C release and caspase 
activation, and this protective effect is abrogated by proteasome inhibitors and Parkin 
mutations 40. Parkin has also been localized to mitochondria in proliferating cells, where it 
has been shown to associate with mitochondrial transcription factor A and to enhance 
mitochondrial biogenesis 41. A Drosophila model has revealed a role for Parkin in 
maintaining mitochondrial function and preventing oxidative stress. Parkin null mutants 
had severe mitochondrial pathology associated with reduced lifespan, apoptosis, flight 
muscle degeneration and male sterility 42. Microarray analysis in these flies revealed up-
regulation of genes involved in oxidative stress and electron transport, including a 
homologue of the mammalian peripheral benzodiazepine receptor, which has been linked 
to the regulation of mitochondrial integrity and is thought to be involved in the regulation 
of mitochondrial swelling, respiration, trans-membrane potential and the prevention of 
oxidative damage to the mitochondria. A genomic screen for modifiers of lifespan in the 
Parkin null flies found the strongest modifier to be the loss-of-function mutations of 
glutathione S-transferase (GSTS1) 43. Re-analysis of the same flies revealed progressive 
degeneration of a select cluster of dopaminergic neurons and evidence of increased 
oxidative damage with increased protein carbonyls compared with controls. Furthermore, 
neurodegeneration was enhanced in GSTS1 null mutants, whereas GSTS1 over-expression 
significantly rescued the Parkin phenotype 44. Mammalian models also support a role for 
Parkin in maintaining mitochondrial function. Deletion of exon 3 of Parkin in mice results 
in nigrostriatal dysfunction and reduced expression of several proteins involved in 
mitochondrial function and oxidative stress, including subunits of complexes I and IV. 
These mice also had decreased mitochondrial respiratory capacity and showed evidence of 
increased oxidative damage 45. Intriguingly, Parkin deficiency in these mice did not cause 
dopaminergic degeneration, which is also observed in exon 2 and exon 3 deletion models 
46,47,48. It will therefore be interesting to determine whether neurodegeneration in these 
models requires an environmental insult such as an oxidative stressor.  
Very recently, several mono-and double-mutant mouse lines expressing high levels of 
doubly mutated human SNCA and/or a targeted deletion of Parkin have been generated. 
These mice show genotype-, age- and region-dependent morphological alterations of 
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mitochondria in neuronal somata, which are restricted to the brain and lacking in skeletal 
muscle cells. These alterations are not accompanied by alterations of the number or the 
size of the mitochondria or by leakage of cytochrome C but in the SN coincide with a 
reduced complex I capacity.  
None of the transgenic animals however developed overt motor disabilities or any gross 
histopathological abnormalities in the analyzed brain regions.  
PINK1 encodes a ubiquitously expressed 581 amino acid protein, which consists of an N-
terminal mitochondrial targeting motif, a highly conserved serine/threonine kinase domain 
and a C-terminal autoregulatory domain. Loss of PINK1 function adversely affects 
mitochondrial function and cell viability under stress. Mitochondrial membrane potential 
(∆ψm) and levels of cell death were measured in a neuroblastoma cell line over-expressing 
mutated PINK1 (G309D) after exposure to an exogenous source of cellular stress, MG-
132, a proteasome inhibitor. Cells over-expressing G309D PINK1 had significantly 
reduced ∆ψm compared with the wild type and increased levels of cell death following 
exposure to stress, but not under basal conditions. Furthermore, cells over-expressing wild-
type PINK1 had higher ∆ψm and lower levels of cell death than cells transfected with 
vector alone 49. Consistent with these results, over-expression of wild-type PINK1 was 
subsequently shown to reduce the release of cytochrome C from mitochondria under basal 
conditions and staurosporine-induced stress.  
Omi/HtrA2 protein has been previously implicated in neurodegeneration, and recently 
associated with predisposition to PD 50. It is a PDZ domain-containing serine protease, and 
also contains an N-terminal mitochondrial targeting motif and a reaper-like motif. 
Omi/HtrA2 is thought to localize to the mitochondrial intermembrane space, where it is 
released into the cytosol during apoptosis to relieve the inhibition of caspases by binding to 
inhibitor of apoptosis proteins (IAPs). Omi/HtrA2 is also able to induce cell death through 
its proteolytic activity. OMI/HTRA2 knockout mice have been shown to display 
parkinsonian phenotypes, including rigidity and tremor 51.  
 
Oxidative stress  
Inhibition of complex I increases the production of reactive oxygen species (ROS) that can 
react with proteins, nucleic acids and lipids causing cellular damage. 
More in general, impaired mitochondrial function is likely to increase oxidative stress and 
might render cells more vulnerable to this and other related processes, including 
excitotoxicity. 
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The most noticeable feature of the PD post mortem brains is the presence of oxidative 
stress as indicated by the presence of elevated levels of lipid peroxidation markers such as 
HNE and malondialdehyde, oxidative damage to proteins (such as nitration of tyrosine 
residues) and nucleic acids, reduced levels of glutathione and oxidized glutathione.  
Dopaminergic neurons may be a particularly fertile environment for the generation of 
ROS, as the metabolism of dopamine (DOP) produces hydrogen peroxide and superoxyde 
radicals, and auto oxidation of dopamine produces DOP quinone and other species, which 
can react with proteins and damage them. Mitochondrial dysfunction may disrupt vesicular 
storage of DOP, causing the increase of free cytosolic concentration of DOP allowing 
harmful DOP-mediated damage to cellular macromolecules.  
Recently, altered ubiquitination and degradation of proteins have been implicated as key to 
dopaminergic cell death in PD. Oxidative stress can impair these processes directly, and 
products of oxidative damage, such as HNE, can damage the 26S proteasome. 
Furthermore, impairment of proteasomal function leads to free radical generation and 
oxidative stress.  
Parkin knockout mice have revealed an essential role for Parkin in oxidative stress 45 and 
Drosophila Parkin mutants show increased sensitivity to oxidative stress 52.  
 
Implication of PINK1 in oxidative stress processes has also been strongly suggested: 
inactivation of Drosophila PINK1 using RNAi suggested that PINK1 maintains neuronal 
survival by protecting neurons against oxidative stress 53. In mammalian cell culture, 
PINK1 protects against oxidative stress-induced cell death by suppressing cytochrome c 
release from mitochondria, with the protective action of PINK1 depending on its ability to 
phosphorylate the mitochondrial chaperone TRAP1 54.  
 
Mutations in the leucine-rich repeat serine–threonine-protein kinase 2 gene (LRRK2) 
represent the most common known cause of familial PD; these mutations also account for 
cases of sporadic, late-onset PD. 
LRRK2 has a conserved serine–threonine kinase mitogen-activated protein kinase kinase 
kinase (MAPKKK) domain, and is a member of the Roc GTPase family. The commonly 
occurring Gly2019Ser substitution takes place in the MAPKKK domain, and the mutation 
augments kinase activity. Although the majority of LRRK2 is present in the cytoplasm, 
approximately 10% of these proteins are associated with the outer mitochondrial 
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membrane, raising the question of whether mutant LRRK2 kinase hyperactivity might 
directly affect mitochondrial function 51. 
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1.2 DJ-1 
DJ-1 gene and protein distribution 
DJ-1 gene spans 24 kb and contains eight exons, the first two are non-coding and subject to 
alternative splicing in mRNA 69. It encodes a small 189-aminoacid protein that is 
ubiquitously expressed and is widely distributed in brain and other tissues. It is conserved 
through different species 70 and determination of crystal structure of human DJ-1 has 
demonstrated that it exists in homodimeric form, essential to retain its biological function 
71. In human brain, DJ-1 has a marked astrocytic expression 70 while neuronal labelling is 
very weak. It never localizes at LBs 72. On the contrary, in the murine brain DJ-1 presents 
both neuronal and glial expression.  
Bader at al. found DJ-1 expression in murine neurons of different neurotransmitter 
phenotypes and in all glial types, such as astrocytes, microglia, and oligodendrocytes. The 
high DJ-1 expression is not confined to a single anatomical area, considering that positive 
immunoreactivity was found in cortical areas, hippocampus, olfactory bulb, amygdala, 
thalamus, locus coeruleus, caudate, putamen, globus pallidus and tinhe deep nuclei of the 
cerebellum 73,74. Within the SN, DJ-1 is localized in both neuronal and glial cells. At the 
cellular level DJ-1 immunoreactivity is found in both cytoplasm and nucleus, and in the 
mitochondrial matrix and intermembrane space 57. This staining is increased in oxidative 
stress conditions suggesting that oxidation promotes the mitochondrial localization on DJ-
1 75.  
DJ-1 functions 
The exact role of DJ-1 protein in health and disease remains mostly unknown. DJ-1 was 
first discovered as a novel oncogene in cooperation with activated ras 76 and its 
overexpression has been reported in several cancers including breast, lung and prostate 77. 
DJ-1 is involved in various cellular processes including cellular transformation, regulation 
of RNA stability, transcriptional activation and in oxidative stress response.  
Initial computational analysis revealed that DJ-1 belongs to the ThiJ-PfpI Superfamily 
containing a ThiJ domain. This domain has been first described in the Large Glutamine 
Amidotransferase superfamily (GAT), enzyme that is involved in the Thiamine synthesis in 
bacteria. However it is also present in chaperones, catalases and proteases. This 
heterogeneity of functions of the members of the ThiJ-PfpI superfamily limits the ability to 
predict the cellular role of the human ortholog. Structural data suggests that DJ-1 
conformation seems to be unfavourable for catalytic activity. Furthermore, the catalytic 
triad Cys-His-Asp/Glu is not conserved across evolution. Olzmann et al., reported that DJ-
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1 exhibits protease activity instead of a molecular chaperone function, which is abrogated 
by the mutation of Cys106Ala 71. The current consensus is on the lack of catalase or 
protease activity.  
Structural comparisons between DJ-1 and Hsp31, a member of the ThiJ-PfpI family, may 
point to a chaperone activity 78. Shendelman et al. showed that DJ-1 acts as a redox-
regulated chaperone. It is activated in an oxidative cytoplasmic environment and inhibits 
the formation of SNCA aggregates in vitro and in vivo 63. These data suggests that DJ-1 can 
mitigate the molecular insults downstream ROS burst suppressing the early step of protein 
aggregation.  
DJ-1 chaperone activity prevents SNCA fibrillation, but only when Cys106 is oxidized to 
sulfinic acid (Cys106-SO2H), while the native DJ-1 and the highly oxidized form of DJ-1 
resulted to be ineffective 79. These results suggest that the oxidation level can affect its 
structure thus impairing its normal function.  
 
DJ-1 is linked to oxidative stress response. DJ-1 undergoes a pI shift from 6.2 to 5.8 upon 
ROS exposure, indicating that it may function as an indicator of oxidative stress 80. Cys 
106 is the most sensitive among all the three cystein residues (i.e. Cys 46, Cys 53 and Cys 
106). Oxidation induces a mitochondrial relocalization of DJ-1 and protection against cell 
death is abrogated in Cys106Ala but not by Cys46Ala or Cys53Ala 58. Two post mortem 
studies of brain samples from PD brains found that acidic isoforms of DJ-1 are more 
abundant in PD compared to controls 70,81. The accumulation of acidic isoforms of DJ-1 
monomer is followed by the enrichment of basic isoforms of DJ-1 dimer in PD/AD brains 
due to protein carbonylation 81.  
DJ-1 displays a protective role against ROS-induced cell death. DJ-1 knock-down by short 
RNA interfering rendered SH-SY5Y susceptible to both hydrogen peroxide (H2O2) and 1-
methyl-4-phenylpyridinium (MPP+). While overexpression of wild type DJ-1 protects from 
oxidative stress, proteasomal inhibition and ER stress 56,80, cells harboring Leu166Pro DJ-1 
mutant become susceptible to death induced by hydrogen peroxide and do not show 
oxidized forms of DJ-1.  
Moreover, a number of studies performed on DJ-1 deficient mouse model supports this 
hypothesis. 
Dopaminergic neurons derived from in vitro differentiated 82 DJ-1-deficient embryonic 
stem cells showed a decreased survival and an increased sensitivity to oxidative stress. 
Comparing the responses to H2O2 of primary cortical neurons from brains of DJ-1+/+, DJ-
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1+/- and DJ-1-/- mice embryos exposed to H2O2  83, DJ-1-/- deficient neurons showed a 20% 
increase in cell death compared to wild type DJ-1+/+ neurons, whereas an intermediate 
amount of cell death was observed in DJ-1+/- neurons suggesting a gene-dosage effect.  
A similar study analyzed the effect of pesticide rotenone on dopaminergic neurons. This 
pesticide inhibits mitochondrial complex I, increasing ROS. Upon rotenone treatment, the 
number of surviving dopaminergic neurons in DJ-1-deficient mice was decreased by 30% 
compared to control DJ-1+/+ neurons. In addition, it has been shown that DJ-1 knock-out  
(KO) mice are more vulnerable to MPTP and restoration of DJ-1 expression in DJ-1 
deficient mice via adenoviral vector delivery mitigated cell death 83. 
Several DJ-1 KO mice were produced independently but none of them showed 
degeneration of dopaminergic neurons per se. Although they showed an age- and task-
dependent motor deficits, and a marked reduction in evoked dopamine overflow in the 
striatum probably due to an enhancement of DAT function in DJ-1 null mice 84,85, 
dopaminergic neuronal loss was present only when they were treated with drugs that cause 
toxicity through mitochondrial complex I inhibition. 
Findings from triple KO studies demonstrated that inactivation of Parkin, DJ-1 and PINK1 
is still insufficient to cause dopaminergic degeneration in mice during their lifespan. These 
results further supported the notion that Parkin, DJ-1 and PINK1 are not absolutely 
required for the survival of nigral neurons. Rather, they likely provide protection to nigral 
neurons against insults, such as oxidative stress, during the decades-long aging process in 
human patients 86. 
A complementary approach to elucidate DJ-1 role in PD is the study of its homologs in 
Drosophila, DJ-1α and DJ-1β. DJ-1α shares 56% of homology with human DJ-1 while 
DJ-1β 52%. They are characterized by distinct temporal and spatial expression pattern. 
Menzies et al. found that DJ-1α is expressed predominantly in testis, with high expression 
level only in the late stages of development, whereas DJ-1β is ubiquitously present, with 
no relevant changes in expression during the development, closely resembling the human 
DJ-1 expression pattern 87. Drosophila lacking DJ-1 activity are fertile, have a normal life 
span and normal number of dopaminergic neurons. Meulener et al. indicated that double 
knock out (DKO) is not deleterious, but it is much more sensitive to agents that induce 
oxidative stress (i.e Paraquat and Rotenone) 88. Loss of DJ-1β expression results in an 
increased survival of dopaminegic neurons due to a compensatory up-regulation of DJ-1α 
in the brain, which is also associated to a decreased sensitivity to Paraquat 87. Yang at al. 
analyzed a DJ-1α knock out fly strain: the specific inhibition of DJ-1a in dopaminergic 
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neurons led to a decrease of TH- positive neuron number, to elevated ROS accumulation 
and hypersensitivity to oxidative stress. These data clearly indicate a protective role of DJ-
1 mostly in oxidative stress response 59.  
 
DJ-1 protective role is also studied through the analysis of its protein-protein interaction 
network. It has been shown that DJ-1 is indispensable for the stabilization of the 
transcriptional regulator NF-E2-related factor-2 (Nrf2). In physiological conditions, its 
expression is maintained at low level by Keap-1 that targets Nrf2 to protein degradation. 
Upon exposure to oxidative stress, Nfr2 translocates into the nucleus, where it forms 
hetero-dimers with other transcription factors (TFs) inducing the expression of antioxidant 
genes whose promoters contain the ARE (Antioxidant Responsive Element) 89. 
 
The anti-apoptotic function of DJ-1 is exerted through its interaction with the death 
associated protein Daxx. DJ-1 sequesters Daxx in the nucleus, preventing its binding and 
consequential activation of Apoptosis Signal Regulating Kinase 1 (ASK-1) 62. DJ-1 is also 
a transcriptional co-regulator of several transcription factors acting on various promoters, 
functioning as a co-activator and as a co-repressor. Xu et al. demonstrated that DJ-1 
interacts with the nuclear proteins p54nrb and pyrimidine tract-binding protein associated 
splicing factor (PSF), two multifunctional regulators of transcription and RNA metabolism, 
highly expressed in brain. DJ-1 blocks the transcriptional silencing and apoptosis induced 
by PSF-binding protein p54nrb antagonizing PSF effects. Interestingly, DJ-1 can activate 
the transcription at the TH promoter, the rate-limiting enzyme for dopamine biosynthesis 
90. DJ-1 prevents the post translational modification of PSF by the Small Ubiquitin 
Modifier SUMO-1. Mutations that abolish the sumoylation of PSF relieve the 
transcriptional repression of the TH promoter by PSF. Interestingly, the same study 
demonstrated that DJ-1 regulates sumoylation in vivo. Lymphoblast from PD patients (both 
carrying deletion of exon 1-5 and the missense mutation Leu166Pro) have a slight 
reproducible increase of SUMO-1-modified high molecular weight complexes, compared 
to patients with wild type DJ-1 or carrying the non-pathogenic mutation Arg98Gln. These 
data indicate that DJ-1 loss results in an accumulation of SUMO-1-modified PSF, leading 
to a decreased DA synthesis. It is worth noting that this effect is specific for SUMO-1 
conjugated proteins, while it does not affect SUMO2/3 conjugated proteins.  
 
Shinbo et al. found that DJ-1 is bound to p53 in vitro and in vivo and that this binding is 
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stimulated by UV radiation. Moreover, DJ-1 restores p53 transcriptional activity inhibited 
by Topors 91, which sumoylates both DJ-1 and p53. DJ-1 is sumoylated by SUMO-1 on the 
conserved Lys 130 and its post-translational modification is induced by UV radiation in a 
p53-dependent manner. The mutant DJ-1 Lys130Arg abrogates cell growth-promoting 
activity with activated ras 92. 
Furthermore, Kim et al. 2005 demonstrated that DJ-1 modulates the phosphatidylinositol 
3-kinase survival pathway by negatively regulating the function of the tumor suppressor 
gene PTEN 77. Abstrakt, a RNA helicase ubiquitously expressed, has been also found to 
stimulate the transforming activity of DJ-1 in rat 3Y1 cells transfected with DJ-1 and 
activated ras 93. 
Indeed, it has been show that DJ-1 affects cell viability by regulating the ERK 1/2 
signalling pathway. Overexpression of wild type (WT)- DJ-1 but not of the L166P mutant 
dramatically increases the phosphorylation of Extracellular signal-regulated kinases (ERK 
1/2). The ERK1/2 signaling pathway is critical for protecting cells against oxidative stress; 
therefore, the increase of ERK1/2 phosphorylation caused by DJ-1 might provide 
protection against subsequent oxidative stress 94. 
By interacting with protein inhibitor of activated STAT member x (PIASx) alpha and with 
DJ-1 binding protein (DJBP,) proteins predominantly expressed in testis, DJ-1 was also 
able to alter their binding to the Androgen Receptor (AR) 95. 
DJBP directly binds to AR in a testosterone-dependent manner and it negatively modulated 
the AR transcription activity by recruiting the histone-deacetylase complexes. DJ-1 
antagonizes this inhibition by the abrogation of the complex and restoring the AR activity.  
 
DJ-1 in Parkinson’s Disease 
After the identification of the PARK-7 locus by van Dujin et al.96, Bonifati et al. have 
shown mutations in the DJ-1 gene in two PARK-7 linked families. The Dutch family 
displayed a large homozygous deletions of exons 1-5 of the DJ-1 gene and an Italian 
kindred harbored a single missense mutation at an highly conserved position, Leu166Pr 97. 
Till now different mutations affecting DJ-1 (including missense, truncating and splice-site 
mutations and large deletions) have been linked to autosomal recessive PD.  
PD families may present missense mutations of DJ-1 in homozygous (L166P, M26I and 
E64D) and heterozygous forms (A104T and D149A) 98. M26I and L166P are the most 
studied DJ-1 missense mutations. Although M26I dimer formation and protein levels 
reported in the literature may vary, differences with WT DJ-1 are small and of unclear 
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biological significance. On the contrary, L166P is very unstable and its expression level 
lower than WT 99,100,101,102.  
Several studies indicate that the mutant Leu166Pro is unstable and thus degraded through 
the UPS 71,103,75. It is worth noting that position 166 is localized in the penultimate C-
terminal a-helix near the dimer interface and the mutation to proline is predicted to 
interrupt the helix 71,104,105. The Leu166Pro mutant is rapidly degraded. Interestingly, 
Leu166Pro tends to form multimeric aggregates 102,101,71. The Leu166Pro monomer has 
been recently shown to possess a different conformation from the wild type DJ-1 and the 
data computational analysis indicates that Leu166 is not located at the subunit surface 
involved in the dimerization. Thus the different conformation of Leu166Pro monomeric 
units might affect the protein-protein interaction repertory 99. 
It has been shown that L166P and M26I mutants share an increased interaction with TRAF 
and TNF receptor-associated protein (TTRAP). This binding occurs in the absence of 
neurotoxic stimuli proving the existence of an altered DJ-1 protein networks in the 
presence of PD-associated missense mutations. Most importantly, M26I and L166P block 
the protective activity of TTRAP inducing a TTRAP-dependent pro-apoptotic pathway that 
involves JNK and p38 MAPKs, a signaling system that plays a central role in 
dopaminergic cell death and PD pathogenesis 106. 
The pathogenic role of other mutants remains to be established. Some of them might be 
simple polymorphisms that predispose to PD, as demonstrated for the Arg98Gln.  
Although DJ-1 mutations account for only a small fraction of early onset PD (1-2%), they 
are the second most frequent cause of recessive forms of PD, after PARK2-linked families.  
Indeed, in the more common sporadic form of PD, total DJ-1 levels were significantly 
lower in the SN region of PD patients compared to health controls 107.  
Clinically, DJ-1-dependent PD is characterized by early onset of parkinsonism (the average 
age is the early 30s), slow disease progression and good initial response to Levodopa. 
Psychiatric and behavioural disturbances (including severe anxiety and psychotic episodes) 
are reported in both original DJ-1 families 108. Further analysis is necessary to investigate 
whether this aspect is more frequent in DJ-1 patients than in other PD forms. 
  23 
DJ-1 in Neurodegeneration 
Immunohistochemical staining for DJ-1 stained Tau inclusions found in several 
neurodegenerative disorders, including Alzeheimer’s disease (AD), Progressive 
Supranuclear Palsy (PSP), Frontotemporal Dementia linked to chromosome 17 (FTDM-
17), and Pick’s Disease (PiD) 70,109,110. Furthermore, DJ-1 antibodies readily labelled 
SNCA glial cytoplasmic inclusions observed in patients with Multisystem Atrophy (MSA) 
109 and PD. As with tau and SNCA, a fraction of DJ-1 protein became markedly insoluble 
in brain from AD, PiD and MSA compared to controls 109,110. Moore et al., (2005) 
monitored the level of detergent-soluble DJ-1 in human post mortem cingulated cortex 
tissue. They found a dramatic increase of DJ-1 levels in the detergent-insoluble fraction in 
PD and Dementia with Lewy Bodies (DLB), indicating that in pathological conditions DJ-
1 can undergo a biochemical modification.  
These data support the notion that different neurodegenerative diseases might share a 
common mechanism in which DJ-1 role needs to be elucidated. 
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1.3 Clinical approaches to Parkinson’s disease 
Current therapy is largely based on a dopamine replacement strategy, primarily using the 
dopamine precursor levodopa. However, chronic treatment is associated with the 
development of motor complications, and the disease is inexorably progressive. 
Furthermore, disease progression is associated with the emergence of features such as 
freezing, falling, and dementia which are not adequately controlled with dopaminergic 
therapies. Indeed, it is now appreciated that these non-dopaminergic features are common 
and the major source of disability for patients with advanced disease. 
Many different therapeutic agents and treatment strategies have been evaluated over the 
past several years to try and address these unmet medical needs, and many promising 
approaches are currently being tested in the laboratory and in the clinic. 
Clinical trials with intrastriatal transplantation of human embryonic mesencephalic tissue 
have shown that grafted DA neurons re-innervate the striatum, restore striatal DA release 
and, in some patients, induce major clinical benefit. Stem cells could provide an unlimited 
source of DA neurons for transplantation. Recent studies demonstrate that cells with 
properties of mesencephalic DA neurons can be produced from stem cells of different 
sources including reprogrammed somatic cells 111.  
Although stem cell research is promising, there are many obstacles still to be overcome. 
The optimal type of stem cell and transplant protocol remain to be defined, cell survival 
after transplantation is limited, and efficacy in animal models has not yet been established 
to exceed or even equal that obtainable with fetal nigral transplantation (which so far has 
failed in clinical trials) 112. Safety issues must be fully addressed preclinically before 
clinical trials can be initiated, particularly with respect to the risk of tumor formation and 
off-medication dyskinesia.  
Trophic factors are proteins that support and protect subpopulations of cells. A number 
have been reported to act on dopaminergic neurons in vitro and in vivo, making them 
potential therapeutic candidates for Parkinson’s disease. All of these candidate factors 
protect dopaminergic neurons if given prior to, or with, selective neurotoxins. Fewer 
trophic factors, primarily Glial-derived neurotrophic factor (GDNF) and its relative, 
neurturin (NRTN; also known as NTN), have been shown to restore function in damaged 
DA neurons after the acute effects of neurotoxins have subsided. A major barrier to clinical 
translation has been delivery. GDNF delivered by intracerebroventricular injection in 
patients was ineffective, probably because GDNF did not reach the target, the putamen, 
and intraputaminal infusion was ineffective. A randomized clinical trial with gene therapy 
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for NRTN is underway, in an attempt to overcome these problems with targeting and 
distribution. Other strategies are available to induce trophic effects in the CNS, but have 
not yet been the focus of human research. To date, clinical trials have focused on 
restoration of function (i.e., improvement of parkinsonism). Protection (i.e., slowing or 
halting disease progression and functional decline) might be a more robust effect of trophic 
agents.  
 
However, gene therapy offers the potential to provide more diffuse distribution of the 
therapeutic protein through the brain target. In MPTP monkeys, gene delivery of GDNF 
was diffusely distributed throughout the striatum, and provided motor benefits, restoration 
of striatal TH staining, and protection of SNpc dopamine neurons.  
 
1.3.1 GDNF 
GDNF supports the development of embryonic dopamine neurons relatively specifically 
115 and is particularly important for postnatal survival of mesencephalic dopamine 
neurons116. It is present in the striatum and despite being named glial-derived growth 
factor, it may reside largely in the striatal medium spiny neurons that receive dopaminergic 
input from the SN 117. GDNF levels in various parts of the brain are reported to be no 
different in parkinsonian than in control patient brains 118. GDNF mRNA expression was 
increased in the putamen of PD patients 119, there is no evidence that loss of GDNF is 
responsible for development of PD. 
A variety of experiments in rodent models have shown that GDNF directly injected into 
the SN or striatum protects dopaminergic neurons from neurotoxins 118,119,120,121. Elevating 
GDNF in the striatum by gene therapy is also protective 122,123,124 Unlike the case with 
Brain-derived neurotrophic factor (BDNF), however, there is also evidence for restoration 
of function of injured neurons by GDNF after toxic insults 118,121,—although restorative 
actions are generally not as dramatic as the neuroprotective actions 118. A series of 
influential studies from Gash, Gerhardt, and co-workers 125 have demonstrated GDNF-
induced improvements in bradykinesia, rigidity, and postural instability in monkeys with 
stable MPTP-induced hemiparkinsonism. In addition to neuroprotective and 
neurorestorative actions, GDNF also has direct effects on dopamine neurons, modulating 
excitability via changes in A-type potassium channels 35. This may be a mechanism by 
which GDNF acutely increases dopamine release 36,120.  
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GDNF signals through a two-component receptor complex consisting of the GPI-linked 
GDNF family receptor alphas (GFRa) and the rearranged during transfection (Ret) receptor 
tyrosine kinase, a previously identified oncogene-related protein. In vitro studies have 
implied that GDNF binds to GFRa, which then forms a complex with Ret, resulting in the 
phosphorylation of a tyrosine residue of Ret.  
The GDNF signaling is mediated through the tyrosine kinase properties of Ret. Activation 
of Ret by GDNF has been shown to result in activation of the Erk and MAP kinase.  
Although GDNF was originally characterized as a potent survival factor for midbrain 
dopaminergic neurons, analysis of KO mice has shown that GFRa1-Ret signaling is not 
essential for the embryonic development of these neurons, illustrating the complex 
network of signaling pathways and compensatory mechanisms that regulate neural 
development. Recently, two groups have reported the generation of different strains of 
mice with the specific deletion of Ret in dopaminergic neurons 129,130. Surprisingly, these 
animals showed normal development and maturation of the nigrostriatal system. A detailed 
study, including dopaminergic neuron number in SNpc and VTA, fiber density in the 
striatum and nucleus accumbens, and dopamine levels, indicated that Ret is not required 
for the maintenance of midbrain dopaminergic neurons in young adult mice. However, in 
one of these studies, Kramer and coworkers found that, only in aged animals, Ret ablation 
leads to a progressive and cell-type specific loss of SNpc dopaminergic neurons and their 
afferents, thereby indicating that Ret is a critical regulator for the long-term maintenance 
of the nigrostriatal system. The significance of Ret signaling for the dopaminergic system 
was additionally studied in knock-in multiple endocrine neoplasia type B (MEN2B) mice 
by introducing the Ret-MEN2B mutation (Met919Thr), which renders the Ret receptor 
tyrosine kinase constitutively active. In this work, the authors showed that constitutive Ret 
activity in mice is sufficient to increase brain dopamine concentration and the number of 
dopaminergic neurons in SNpc 131, 30. 
 
1.3.2 RET 
In 1996, the transmembrane receptor tyrosine kinase Ret was identified as a GDNF 
receptor. Ret is shared by all of the GFLs as their common signaling receptor.  
Mice lacking Ret die a few hours after birth owing to kidney agenesis and show absence of 
enteric and many parasympathetic neurons 133. 
Ret is strongly expressed, both at the mRNA and protein level, in adult dopaminergic 
neurons of SN and VTA.  
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Conditional KO mice for Ret receptor show normal development and maturation of 
nigrostriatal system. In ageing mice ablation of Ret leads to a progressive and cell-type-
specific loss of SNpc neurons and their projections into the striatum. Ret is specifically 
required for long-term target innervation. In aged Ret mutant mice, the extent of target 
innervation loss exceed the degree of cell loss. Mutant mice show also reduced levels of 
evoked dopamine release but not of total dopamine amounts in the striatum. This effect is 
likely due to the fact that Ret mutants loose neurons during ageing which leaves more time 
for compensatory mechanisms. 
Moreover, Ret ablation resulted in gliosis in the striatum and to macroglial activation in 
the SN. 
The absence of RET in midbrain dopaminergic neurons is associated with modest 
decrements in locomotor activity, whereas most sensorimotor functions seem to be 
unaffected.  
So far there is no evidence that PD can be caused by mutations in the Ret gene itself 
because analysis of polymorphisms have not shown any association with PD but recently 
Ret expression level has been studied in PD drug models. Following MPTP treatment Ret 
was found strongly down-regulated in the striatum of adult mice. Indeed, 6-
hydroxydopamine and rotenone reduce expression Ret mRNA in the SN and VTA. These 
studies provide evidence that lack of neurotrophic support, due to down-regulation of Ret 
receptor, precedes neuronal degeneration. 
Recently, Elvidge and collegues have demonstrated a strict correlation existing between 
the HIF-1a stabilization and a strong down-regulation of the GDNF receptor Ret 134. This 
result pointed out to a possible common pathological mechanism shared by different 
neurodegenerative disorders. 
Therefore, down-regulation of Ret indicates that trophic support may be limited not to 
reduced levels of the trophic factor itself and by the loss of its receptor, leading to a 
diminished capacity to transduce the actions of neurotrophic factors. This in turn leads to 
the lack of neurotrophic support and neuronal degeneration.   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2. AIMS 
 
Although the exact cause of PD is unknown, familial cases have contributed to the 
understanding of the molecular pathways involved in the common forms of PD.  
 
DJ-1 mutations are the second most frequent cause of recessive forms of PD after PARK2-
linked cases. 
 
Moreover, even in the more common sporadic form of PD, total DJ-1 levels were found 
significantly lower in the SN region of PD patients compared to healthy controls 107 
suggesting that the altered functional DJ-1 level could account not only for the hereditary 
form of the disease but also be involved in the onset of sporadic cases. 
 
Due to its multifunctional properties, the causative link between the lack of functional DJ-
1 and the onset of Parkinson’s disease is still matter of debate 
Thus, understanding the relationship of DJ-1-mediated neurodegeneration to PD will have 
a powerful impact on the development of disease-modifying therapies for PD.  
The purpose of this thesis is to elucidate these molecular mechanisms by a multi-step 
approach:   
  
1. developing a cellular model to study the effect of loss of DJ-1 was developed;  
  
2. gene expression profile to find out molecular pathways altered by the loss of DJ-1 
  
3. analysis and validation of pathways altered by DJ-1 loss of function 
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Results presented in this thesis are part of the following manuscript in preparation: 
 
- Foti R., Zucchelli S., Biagioli M., Roncaglia P., Krmac H., Calligaris R., Gustincich S. 
“Parkinson disease associated DJ-1 is required for the expression of GDNF receptor Ret in 
human neuroblastoma cells” 
 
Indeed, during these years I have been involved in several different projects that are not 
presented in this thesis but are part of the following pubblications and manuscript: 
 
- Zucchelli S., Vilotti S., Scotto Lavina Z., Calligaris R., Biagioli M., Foti R., Casseler C., 
De Maso L., Pinto M. and Gustincich S. 
“Aggresome-forming TTRAP mediates pro-apoptotic properties of Parkinson’s Disease-
associated DJ-1 missense mutations”  
Cell Death and Differetiation Cell. 2009 Mar;16(3):428-38 
 
- Calligaris R., Bellarosa C., Foti R., Roncaglia P. Giraudi P, Krmac H., Tiribelli C. and 
Gustincich S.” 
“A transcriptome analysis identifies molecular effectors of unconjugated bilirubin in 
human neuroblastoma sh-sy5y cells.  
Submitted to BMC Genomics 
 
- Deganuto M, Cesaratto L, Bellarosa C , Calligaris R, Vilotti R, Renzone G, Scaloni A, 
Foti R., Gustincich S,Quadrifoglio F, Tiribelli C , Gianluca Tell G. “A proteomic approach 
to the bilirubin-induced toxicity in neuronal cells reveals a protective function of DJ-1 
protein.” Submitted to Proteomics 
 
-  Vilotti S., Zucchelli S., Scotto Lavina Z., Foti R. and Gustincich S. 
 “Parkinson’s disease associated DJ-1 mutant L166P hampers nucleolar localization of 
TTRAP and p53 in response to proteasomal impairement” 
Manuscript in preparation 
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3. RESULTS 
 
3.1.1 Generation of inducible stable cell lines expressing RNAi against DJ-1 
To mimic the loss-of-function effects as seen in PD patients with DJ-1 mutations, we used 
DJ-1-specific siRNA constructs to inhibit the synthesis of endogenous DJ-1 in the human 
SH-SY5Y neuroblastoma cell line. We screened among three different sequences for the 
best silencing efficiency in transient transfection 
 
 
Fig. 4 - Western Blot analysis of DJ-1 expression level in SH-SY5Y after transient transfection of 
siRNA#Embo, siRNA#93 and siRNA#779 constructs and of scramble sequence.  
 
Since siRNA#93 showed the same DJ-1 protein level than the empty vector, we decided to 
use siRNA#779 and siRNA#Embo siRNA (siRNA#1 and siRNA#2 respectively) to 
establish stable cell lines silenced for DJ-1 and the scramble sequence to establish a control 
cell line.  
Several attempts of constitutive expression of very efficient siRNAs against DJ-1 failed for 
the positive selection of cells that maintained a low but relevant amount of endogenous DJ-
1 protein. 
Therefore, we decided to take advantage of an inducible RNAi approach, in which the 
expression of the interfering sequence is controlled by the tetracycline repressor (TetR) 
system. Inhibition of DJ-1 expression is thus achieved when the inducing agent 
(tetracycline or doxycycline) is present. This allows the selection of stable clones in 
absence of interference. 
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We first generated stable SH-SY5Y cells upon transfection of a plasmid that directs the  
espression of the TetR protein under a strong constitutive promoter. We screened among 
24 clones for the most abundant expression of the Tet-Repressor protein and we selected 
P17 clone as recipient clone for inducible RNAi sequences. 
 
 
 
Fig. 5 – Generation of TetR stable cells. SH-SY5Y cells stably transfected with Tet-Repressor (TetR) were 
generated. Independent monoclonal populations were selected and analyzed for TetR expression. Western 
Blot analysis for TetR representative clones are shown. 
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We tested various conditions for the silencing induction in transient transfection and we 
choose 7 days of induction for the strongest down-regulation of DJ-1 mRNA level but, as 
expected for its high stability, 10 days of induction for the down-regulation of the protein 
level. 
 
Tested Conditions  
mRNA analysis  Protein analysis 
Time  Concentration Time  Concentration 
24 hrs 1µg/mL; 2.5 µg/mL; 5 
µg/mL; 10 µg/mL 
7 days 1µg/mL; 2.5 µg/mL; 
48 hrs 1µg/mL; 2.5 µg/mL; 5 
µg/mL; 10 µg/mL 
10 days 2.5 µg/mL; 
5 days 1µg/mL; 2.5 µg/mL; 5 
µg/mL 
14 days 2.5 µg/mL; 
7 days 1µg/mL; 2.5 µg/mL;   
 
Tab. 2 – Tested conditions for silencing’s efficiency. 
  
By a second stable transfection, we were then able to generate RNAi inducible stable cell 
lines. To monitor the presence of off-target effects, we used both the two different RNAi 
molecules siRNA#1 and siRNA#2 and, as an additional control, we established inducible 
cell lines with the scramble sequence.  
 
 
Fig. 6 – Generation of inducible stable cell lines. Schematic representation of inducible expressing system.  
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All three interference sequences were under the control of TetR. For each of the cell lines 
we selected 24 single clones in G418, and multiple, independently isolated clones were 
scored for Doxycycline (Doxy) inducible down-regulation of DJ-1 expression level by 
quantitative Real Time PCR (qPCR). Scramble clones were used as internal control for 
endogenous physiological DJ-1 levels. To exclude clonal effects, two independent clones 
for each cell lines were selected and analyzed. Since, when comparing not-induced and -
induced siRNA#1 clones, we observed a partial leakage of the Tet promoter in Dox-
untreated cells, all our experiments were carried out comparing DJ-1-interfered clones with 
scramble controls. 
 
As shown in figure 7, siRNA#1 causes a profound decrease in DJ-1 expression level, 
achieving a >90% silencing. These results were consistent in the two independent selected 
clones (B and G). siRNA#2 proved to be only partially effective, with a 50% reduction in 
DJ-1 levels as compared to scramble clones. These data are in agreement with previously 
results that used the same sequence in transient transfection experiments 80. Only one clone 
was obtained during the selection process for siRNA#2 since most of the clones didn’t 
show any variation in DJ-1 levels.  
 
Fig. 7 - qPCR of DJ-1 expression level before and after 10 days of doxycycline-induction. All experiments 
were performed in triplicate, and error bars indicate SD.  
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To assess the effects of DJ-1 mRNA silencing on the levels of DJ-1 protein, we monitored 
the down-regulation of DJ-1 by western blot analysis and by immunofluorescence. 
 
 
 
Fig. 8 – Analysis of DJ-1 protein level in absence and in presence of doxycycline-induction. Western Blot 
(A) and Immunofluorescence (B) analysis of DJ-1 expression level in inducible siRNA clones and scramble 
clones. Scal bar 50 µm 
 
As shown in figure 8, after induction, DJ-1 protein level were almost undetectable in  both 
siRNA#1 clones compared to scramble while the reduction observed in siRNA#2 clone is 
only partial. 
 
We then decided to proceed our analysis in both clones siRNA #1 that better represent the 
pathological condition of a homozygous loss of function. 
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3.1.2 Silencing kinetics 
To monitor the kinetics of silencing, we measured DJ-1 mRNA levels by qPCR at 3, 6 and 
10 days of Doxy induction. A 90% reduction of DJ-1 mRNA level was present already 
after 3 days of induction with Doxy and it persists to the 10th day.  
We found that the amount of residual DJ-1 protein was reduced to almost undetectable 
levels in siRNA#1 as compared to scramble clones only after 10 days of Doxy treatment. 
Kinetic experiments showed that DJ-1 protein started to decrease at 6 days (70%) and 90% 
was knocked down after 10 days. These results are compatible with the half-life of the DJ-
1 protein as measured in cell culture 80. 
 
Fig. 9 – Kinetic of silencing in not induced and after 3, 6 and 10 days of induction in siRNA#1 clones and 
scramble clones; A) qPCR of DJ-1 mRNA level; B) Western Blot analysis of DJ-1 protein level; C) 
Immunofluorescence analysis of DJ-1 protein. All experiments were performed in triplicate, and error bars 
indicate SD. Scale bar 20 µm 
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3.1.3 Cellular Phenotype 
Concomitantly with the complete silencing of DJ-1 we observed a modification of  
intercellular contacts with the formation of mounds of cells and the loss of peripheral cells’ 
monolayer. 
 
 
Fig. 10 – Visible phenotype. Rapresentative image of siRNA#1 clones and scramble after 10 days of 
silencing induction. Scal bar 50 µm. 
 
Interestingly, the spheroids formation was strictly correlated to silencing kinetic. As shown 
in fig. 11, the first appeareance of spheroids is after six days of silencing induction, 
perfectly following the kinetic of DJ-1 protein level downregulation. 
 
Fig. 11 – Kinetic of silencing. Rapresentative images both of siRNA#1 clones and both scramble clones in 
not induced and after 3, 6 and 10 days of silencing induction. Scal bar 20 µm 
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3.1.4 FACS analysis of the cell cycle 
To further characterize the silenced clones, we performed Fluorescent Activated Cell 
Sorting (FACS) analysis of the cell cycle. We compared the FACS profiles of both 
scramble clones with profiles of both silenced clones of siRNA#1. We couldn’t find any 
statistically relevant differences between scramble and silenced clones. 
 
Fig. 12 – FACS analysis of cell cycle of both scramble clones and both siRNA#1 clones after silencing. All 
experiments were performed in triplicate, and error bars indicate SD.  
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3.2.1 Affymetrix Gene Chip Analysis 
 
To understand molecular mechanisms altered by the loss of DJ-1 we took advantage of the 
Affymetrix technology to perform gene expression profile of silenced clones. 
We performed gene expression profiling on the two clones containing siRNA#1 (B and G) 
and two scramble ones (H and M). RNA samples were collected after 10 day of Doxy-
treatment, a condition when DJ-1 protein expression is almost completely eliminated. 
Samples were hybridized on Affymetrix GeneChip Human Genome U133A 2.0. Data 
obtained from two independent experiments for each line were collected and analyzed. 
 
To ensure that changes warranted further study, statistical analysis was performed with the 
SAM module (Significance Analysis of Microarrays 159). Applying a False Discovery Rate 
(FDR) of 10% we found 166 genes that were differentially regulated in both siRNA#1 
clones versus the two scramble ones. with 102 down-regulated and 64 up-regulated 
transcripts. 
 
By Gene-Ontology analysis, we clustered the down-regulated genes to signal transduction, 
cell motility, developmental process, cell migration and synaptic transmission biological 
processes. Up-regulated genes, clustered mainly in biological processes involving 
chromatin assembly, cytoskeleton organization and biogenesis, cell projection 
morphogenesis, neurogenesis and regulation of transcription (see Supplementary A. Tab. 
1).  
 
A higher stringent analysis (FDR of 0%) was then applied to reduce the number of false 
positive genes that were differentially regulated in both B and G siRNA#1 clones versus 
the two scramble ones. This stringent filtering produced a list of 10 genes that were 
increased and 16 genes that were decreased in cells with siRNA#1 (Tab. 2). As expected, 
DJ-1 was identified among the down-regulated genes. 
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Gene name Gene symbol 
Fold 
change  
glutamate receptor, metabotropic 8 GRM8 6,08 
cell division cycle 42 (GTP binding protein, 25kDa) CDC42 4,40 
calcium/calmodulin-dependent protein kinase (CaM 
kinase) II beta CAMK2B 4,05 
latrophilin 3 LPHN3 3,84 
AP2 associated kinase 1 AAK1 3,49 
polypyrimidine tract binding protein 2 PTBP2 2,95 
plakophilin 4 PKP4 2,44 
PDZ and LIM domain 3 PDLIM3 2,18 
eukaryotic translation initiation factor 2-alpha kinase 1 EIF2AK1 1,97 
chromosome 8 open reading frame 33 C8orf33 1,60 
electron-transferring-flavoprotein dehydrogenase ETFDH -1,45 
v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog F (avian) MAFF -1,48 
dedicator of cytokinesis 9 DOCK9 -1,52 
protocadherin alpha 12 PCDHA12 -1,58 
integrin alpha FG-GAP repeat containing 1 ITFG1 -1,60 
chromosome 5 open reading frame 15 C5orf15 -1,71 
ST3 beta-galactoside alpha-2,3-sialyltransferase 6 ST3GAL6 -1,73 
mitofusin 1 MFN1 -1,74 
septin 6 SEPT6 -1,83 
RAB21, member RAS oncogene family RAB21 -1,94 
calcium binding and coiled-coil domain 2 CALCOCO2 -2,01 
PDZ and LIM domain 5 PDLIM5 -2,08 
integrin, beta 1  ITGB1 -2,24 
filamin A, alpha (actin binding protein 280) FLNA -2,72 
ret proto-oncogene RET -3,60 
Parkinson disease (autosomal recessive, early onset) 7 PARK7 -7,42 
Tab. 3 - Summary of Affymetrix GeneChip analysis. 
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3.2.2 Validation of microarray data 
To validate microarray data, we performed qPCR analysis on the top-three mostly up-
regulated (GRM8, CDC42, CAMKIIB) and down-regulated (ITGB1, FLMNA, RET) 
genes on clones containing siRNA#1. Changes in gene expression revealed by Affymetrix 
profiling were all confirmed by qPCR (Fig. 13 a, b). We found that the metabotropic 
glutamate receptor 8 (GRM8) was up-regulated more than 15-fold compared to scramble 
clones, while a 7-fold of induction was observed for the GTPase cell division cycle 42 
(CDC42) and 2-fold for the calcium/calmodulin-dependent protein kinase (CaM kinase) II 
beta (CAMKIIB). A 2-fold reduction was indeed confirmed for integrin, beta 1 (ITG-β1), 
filamin a (FLMNA) and of 9-fold for ret proto-oncogene (RET) 
 
 
Fig. 13 - qPCR analysis of mRNA expression of both clones siRNA#1 and scramble clones. Validation of 
the most (A) up- and (B) downregulated genes obtained from Affymetrix analysis. All experiments were 
performed in triplicate, and Data are presented as means ± SEM. 
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3.2.3 Analysis of Ret expression 
Since conditional genetic ablation of Ret in DA neurons provoked progressive motor 
dysfunctions and GDNF, the Ret ligand, is a well known neurotrophic factor for DA cells, 
we decided to focus our attention on the effects of DJ-1 loss on Ret expression. 
We first showed by qPCR that Ret expression level was strongly reduced in B and G 
siRNA#1 versus scramble clones (9-fold). 
To ascertain the specificity of DJ-1-mediated Ret down-regulation and to monitor the 
significance of the DJ-1 dosage, we analyzed Ret mRNA levels also in siRNA#2 clone 
(Fig. 14a). Importantly, a strong Ret down-regulation (6-fold) was observed even in this 
clone, proving a causal relationship between DJ-1 and Ret transcripts levels and excluding 
an off-target effect.  
By western blot analysis, Ret protein resulted strongly reduced by loss of DJ-1 (>90% 
decrease) as shown by the almost complete disappearance of Ret-specific immunostaining 
(Fig. 14b) in both siRNA#1 clones. Compatible with qPCR results and the partial reduction 
of Ret mRNA, Ret protein levels in siRNA#2 clone were lowered, although to a lesser 
extent. 
Therefore, we can conclude that in human neuroblastoma cells, loss of DJ-1 expression 
decreases the levels of Ret, the co-receptor for GDNF. 
 
 
Fig. 14 - Analysis of RET expression level in both siRNA#1 clones, siRNA#2 clone and scramble clones. A) 
qPCR analysis of mRNA RET expression level, scramble and siRNA#1 bars indicate average value between 
two different clones, All experiments were performed in triplicate, and data are presented as means ± SEM; 
B) Western blot analysis of RET protein level in siRNA#1 clones, siRNA#2 clone and scramble clones 
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3.2.4 In vivo analysis 
 
We try to validate the down-regulation of RET expression level also in DJ-1 KO mice. We 
extracted RNA from the ventral midbrain and the striatum of 5 DJ-1 WT, 5 heterozygous 
(HZ) and 5 KO mice, 3 months and 5 months old, and analyzed RET expression level by 
qPCR. We did not find significant alteration in KO mice compared to age-matched control.  
 
 
3.3.1 Loss of DJ-1 stabilizes Hypoxia Inducible Factor 1 alpha (HIF-1a) and triggers 
hypoxia.  
 
Among the various transcription factors (TF) that regulate Ret transcription, hypoxia 
inducible factor 1 alpha (HIF-1a) was a good candidate for mediating DJ-1 and Ret 
interplay. Upon stabilization, HIF-1a has been shown to repress Ret at mRNA level 40.  
To verify that HIF-1a was able to down-regulate also Ret protein level in human 
neuroblastoma, we stabilized HIF-1a treating SH-SY5Y with cobalt chloride (CoCl2) for 6, 
12 and 24 hours and measured HIF-1 and Ret protein level by western blot. As soon as 
after 6 hours of treatment HIF-1a was strongly stabilized and the stabilization correlated 
with a reduction of Ret protein level. Importantly, after 24 hours of treatment, Ret protein 
level was undetectable (Fig. 15).  
 
 
Fig. 15 - Western blot analysis of RET and HIF-1a protein level in SH-SY5Y cells treated with cobalt 
chloride 
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Since HIF-1a expression is mainly regulated at the post-transcriptional level, we 
investigated by western blot HIF-1a protein expression in siRNA#1 clones as compared to 
scramble ones. Interestingly, HIF-1a protein was stabilized concomitantly to Ret down-
regulation in both siRNA#1 clones (Fig. 16).  
 
Fig. 16– Western blot analysis of HIF-1a and RET protein level in both scramble and siRNA#1 clones 
 
 
Since HIF-1a is stabilized in hypoxic conditions, we then asked whether the absence of DJ-
1 was sufficient to cause a hypoxic state. Using Hypoxyprobe we were able to verify 
cellular hypoxia, a strong staining for hypoxic chemical adducts was revealed in both 
clones silenced for DJ-1 while absent in controls (Fig. 17). 
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Fig. 17 - Analysis of hypoxia condition in silenced clones. Hypoxyprobe staining of both scramble and 
siRNA#1 clones. Scale bar 50 µm 
 
Therefore, DJ-1 loss provoked a generalized hypoxic condition in SH-SY5Y 
neuroblastoma cells. 
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3.3.2 Loss of DJ-1 induces ROS accumulation.  
Since hypoxia increases ROS production 40 and DJ-1 is involved in intracellular redox 
homeostasis, we asked whether in absence of DJ-1 there was an increased ROS production 
in our in vitro cell model. To this purpose, we took advantage of a fluorescent probe that 
quantifies ROS production (ROS- probe) as dihydroethidium (DHE) staining for 
superoxide. 
As shown in Fig. 15, after induction of DJ-1 interference, an increase of free radical 
species was detected compared to controls (Fig. 18). 
 
 
Fig. 18 – Analysis of ROS level in silenced clones. DHE staining of both scramble and siRNA#1 clones. 
Scale bar 50 µm 
 
Therefore, DJ-1 loss in SH-SY5Y neuroblastoma cells provokes an accumulation of toxic 
ROS species. 
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3.3.3 DJ-1 is able to rescue Ret expression. The role of its ROS scavenging activity.  
We then re-introduced DJ-1 expression in the inducible siRNA#1 clones to prove that Ret 
down-regulation was not an off-target effect of this RNAi molecule. Taking advantage that 
siRNA#1 sequence was designed on the 3' noncoding UTR region, considerable amounts 
of DJ-1 protein were ectopically expressed upon transfection of 2xflag-DJ-1 in both 
siRNA#1 and scramble clones.  
As shown in Fig. 19, the re-introduction of DJ-1 protein restored Ret expression in 
siRNA#1 clones. Ret protein levels were slightly less than in the scramble controls, 
probably due to transfection efficiency.  
 
Fig. 19 – DJ-1 rescue in silenced clones. Western blot analysis of RET protein level in siRNA#1 and 
scramble silenced clones in absence and in presence of Flag-DJ-1. 
 
We analyzed also HIF-1a protein level. Upon DJ-1 transfection we found also a partial 
reduction in HIF-1a protein level in siRNA#1 clones while no change was found in 
scramble clones.  
 
Fig. 20 – Analysis of HIF-1a protein level after DJ-1 rescue. A) Representative panel of Western blot 
analysis of HIF-1a protein level in absence and in presence of Flag-DJ-1. B) Densitometric analysis of 
immunoreactivity bands. All experiments were performed in triplicate for both siRNA#1 clones, and data are 
presented as means ± SEM. 
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3.3.4 DJ-1 mutants are unable to rescue RET expression level 
We than asked whether Ret down-regulation may also play a role in PD cases with DJ-1 
missense mutations. To this purpose we transfected the PD-associated L166P mutation 
(2xflag-L166P) into siRNA#1 clones and control clones. As expected, L166P protein 
levels were lower than WT DJ-1 for its well known instability. Interestingly, L166P 
mutants were not able to rescue Ret expression as assayed by western blot. Indeed, since 
ROS scavenging occurs through oxidation of DJ-1 at the residue C106, we monitored 
whether this activity was involved in Ret regulation. By transfecting a 2xflag-C106A into 
siRNA#1 clones, we proved that DJ-1 scavenging activity is required for Ret expression 
since the ectopic expression of DJ-1 C106A did not have any effect on Ret expression. 
 
Fig. 21 – RET rescue. Western blot analysis of RET protein level after transfection of DJ-1 wild type, 
C106A and L166P mutants. 
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3.3.5 DJ-1 rescue of hypoxia 
To further prove that the establishment of hypoxic state was strictly dependent on the loss 
of DJ-1 and to exclude off target of siRNA#, we performed rescue experiment transfecting 
DJ-1 in both silenced clones and evaluating hypoxia in transfected cells. We measured 
Pearson’s correlation as colocalization coefficient. As shown in Fig. 23, both scatter plot 
and Pearson’s coefficient indicate a negative correlation bteween the presence of hypoxic 
condition and the presence of Flag-DJ-1. It’s noteworthy that only cells transfected with 
DJ-1 show negative Person’s correlation in contrast with cells transfected with only Ds-
Red where persists the hypoxic state as revealed by the positive correlation illustrated by 
scatter plot and Pearson’s coefficient. 
 
Fig. 23 – Hypoxia rescue. A) Hypoxyprobe and Flag-DJ-1 staining after Flag-DJ-1 transfection. 
Representative scatter plot of colocalization studies; B) Hypoxyprobe and Ds-Red staining after Ds-Red 
transfection. Representative scatter plot of colocalization studies. *P < 0.05. Scale bar 20 µm 
  49 
4. DISCUSSION 
 
Originally identified as an oncogene, DJ-1 is a ubiquitous redox-responsive cytoprotective 
protein with diverse functions. In addition to cell-autonomous neuroprotective roles, DJ-1 
may be up-regulated in reactive astrocytes, in chronic neurodegenerative diseases as well 
as in stroke. DJ-1 is an important redox-reactive signaling intermediate controlling 
oxidative stress after ischemia, upon neuroinflammation, and during age-related 
neurodegenerative processes41. 
 
In 2003 mutations and deletions of this gene have been associated with inheritable forms 
of PD 80. Recently, reduction of DJ-1 expression level was also found in post-mortem brain 
of sporadic PD patients 33.  
 
Missense mutations of DJ-1 found in PD patients may be in homozygous (L166P, M26I 
and E64D) and heterozygous forms (A104T and D149A) 98. Among of them, M26I and 
L166P are the most studied DJ-1 missense mutations.  
Although M26I dimer formation and protein levels reported in the literature may vary, 
differences with WT DJ-1 are small and of unclear biological significance.  
On the contrary, L166P is very unstable and its expression level lower than WT 99,100,101,102.  
The different conformation of Leu166Pro monomeric units might affect the protein-protein 
interaction repertory 99. L166P and M26I mutants share an increased interaction with 
TRAF and TNF receptor-associated protein (TTRAP). This binding occurs in the absence 
of neurotoxic stimuli proving the existence of an altered DJ-1 protein networks in the 
presence of PD-associated missense mutations. Most importantly, M26I and L166P block 
the protective activity of TTRAP and induce a TTRAP-dependent pro-apoptotic pathway 
involving JNK and p38 MAPKs, a signaling system that plays a central role in 
dopaminergic cell death and PD pathogenesis 106.  
Moreover, studies performed by Nishinaga and colleagues have shown a low correlation 
between gene expression profiles performed on DJ-1 knock-down cells and L166P- 
carryng cells. This work suggests that gain of function can occur in L166P-carrying cells. 
Gain of function of L166P DJ-1 might include change of transcription factors that bind to 
DJ-1 141.  
How these mutants abolish or modify DJ-1 functions is a matter of debate, as a common 
mechanism of action for the various DJ-1 mutants is still lacking. 
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In order to unveil molecular mechanisms underlying neurodegenerative processes, in vivo 
and in vitro models without a functional DJ-1 have been developed revealing the protective 
role of DJ-1 against oxidative stress.  
 
KO mice for DJ-1 showed a progressive decline in selected motor tests, increased striatal 
dopamine and evoked dopamine overflow in the striatum. However, these models did not 
completely recapitulate the key symptoms of the disease since they did not show changes 
in the number of nigral dopaminergic neurons 34,86,36. 
Mouse genetic models of the disease have often been limited by the inherent variability of 
animal experiments, the limited mouse life span, and the difficulties in manipulating whole 
animals. Instead, genetic in vitro cellular models are more readily amenable to molecular 
dissection of disease mechanisms. 
 
In vitro model of knocked-down DJ-1 have been useful to elucidate its protective role in 
cellular response to oxidative stress induced by PD related toxins like MPTP and Paraquat. 
Dopaminergic neurons derived from in vitro differentiated 82 DJ-1-deficient embryonic 
stem cells showed a decreased survival and an increased sensitivity to oxidative stress. 
 
To this purpose human neuroblastoma SH-SY5Y cells have been widely adopted as 
cellular model to study PD for their high dopamine-β-hydroxylase activity. In particular, 
experiments from several laboratories using SH-SY5Y cells have clearly demonstrated the 
protective activity of overexpressed DJ-1 against neuronal apoptosis through various 
molecular mechanisms (molecular chaperone, regulator of transcription, scavenger of ROS 
species). 
 
In this study we have been able to generate inducible stable cell lines interfered for DJ-1 
expression. The use of an inducible promoter allowed us an unbiased selection of clones in 
absence of the interference. 
We adopted two different RNAi sequences with two different silencing’ efficiency. With 
the siRNA#1 we have been able to obtain inducible stable cell lines in which both DJ-1 
mRNA and DJ-1 protein level were almost undetectable.  
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This model allowed us to mimic more closely the pathological DJ-1 loss of function, since 
the homozygous mutations or deletions of this gene have been found associated to 
neurodegeneration. 
To our knowledge it’s the first time that, using RNAi technology, it was possible to select 
clones almost completely devoid of DJ-1. Previous attempts have failed for the remaining 
of residual DJ-1 protein activity. 
With the second inducible stable cell line (siRNA#2), we had only a partial reduction of 
DJ-1 expression level comparable with heterozygous deletion/mutations. 
 
Interestingly silencing kinetics was strictly correlated with an alteration of visible 
phenotype. Wild type human neuroblastoma cells can form mounds of undifferentiated 
cells, which then spread differentiated cells into the surrounding area. This growth 
formation can be referred as the "over-easy formation" and show colonies with a loose 
peripheral network of cells 43. Concomitantly with the silencing kinetics, when DJ-1 
protein starts to be strongly down-regulated (after 6 days of induction) both silenced clones 
almost completely lost the peripheral monolayer of cells and preferred to grow as colonies. 
We confirmed by western blot analysis of neuronal markers a reduction of the 
differentiated component in both silenced clones compared to scramble ones. 
 
Given the oncogenic role of DJ-1 we asked whether its absence could alter the cell cycle of 
silenced clones. The absence of DJ-1 did not affect cell cycle of both silenced clones 
compared to scramble demonstrating that cells lacking DJ-1 were in an active proliferating 
status. 
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Taking advantage of the clones showing the strongest down-regulation of DJ-1, we 
performed gene expression analysis to unveil molecular mechanism altered by the loss of 
DJ-1 on both silenced clones compared to scramble. Previous gene expression analyses 
performed in DJ-1 knock-down cells and in PD-derived mutant L166P-carrying cells in 
other cellular systems have identified genes related to apoptosis, oxidative stress and 
neurotoxicity confirming the role of DJ-1 as transcriptional regulator 38. 
 
Here we demonstrated that the strong down-regulation of DJ-1 was responsible for the 
alteration of genes involved mainly in nervous system development and cell adhesion. 
Among them, we focused our attention on the Glial cell line-Derived Neurotrofic Factor 
(GDNF) receptor Ret. This result has high relevance for its implication in Parkinson’ 
Disease. GDNF is able to promote neurite outgrowth and sprouting of adult midbrain DA 
neurons, the neuronal population mainly affected in the disease116. In addition to 
neuroprotective and neurorestorative actions, GDNF also has direct effects on dopamine 
neurons, modulating excitability via changes in A-type potassium channels 47. 
Ret expression level, both transcript and protein, was strongly down-regulated by the 
absence of DJ-1. Moreover, we found that the observed Ret down-regulation was strictly 
correlated with the residual quantity of DJ-1, although interference clones expressing 50% 
of DJ-1 levels showed a modest but consistent decrease of Ret expression level. It’s 
noteworthy that only a strong down-regulation of DJ-1 was able to completely inhibit the 
expression of Ret receptor and the importance of this result became striking considering 
that only the homozygous deletion of DJ-1 has been associated to PD onset.  
The down-regulation of Ret has strong implications for PD, since it’s already well known 
that mice conditional knock-out for this receptor show a progressive and late degeneration 
of dopaminergic neurons, main feature of pre-symptomatic PD 40. Nonetheless, so far there 
is no evidence that PD can be caused by mutations in the Ret gene itself because analysis 
of polymorphisms have not shown any association with PD41 but it’s known that PD 
related toxins like MPTP, Rotenone and 6-hydroxydopamine are able to down-regulate Ret 
expression level both in vitro and in mice SN and VTA42. Down-regulation of Ret could 
implicate that GDNF neurotrophic support to dopaminergic neurons may be impaired by 
DJ-1 loss and precede neuronal degeneration. 
Interestingly, in wild type human neuroblastoma cells GDNF is secreted in the medium, it 
stimulates Ret by a cell-autonomous mechanism and, upon retinoic acid treatment, it 
contributes to SH-SY5Y differentiation 46. Starting from this observation, the down-
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regulation of Ret receptor could account for the reduction of neuronal phenotype in clones 
lacking of DJ-1 since these cells are unable to respond to the autocrine GDNF stimulus.  
 
However, we have not been able to validate Ret down-regulation in vivo. This could be 
due to the inherent variability of animal experiments and to the limited mouse life span. 
However, this may be due to the compensatory mechanisms that account for the increase 
of other scavenger proteins like GPx, previously found in adult DJ-1(-/-) 54. On the other 
hand, it will be interesting to analyze Ret expression levels in older mice. It’s noteworthy 
that DJ-1 KO mice showed slight motor symptoms only after 11 months from the birth. 
Interestingly, conditional Ret KO mice showed a 40% reduction of TH positive fibers only 
in 1 year old mice while a 63 % reduction was observed after 2 years 60. 
 
By compiling a list of all transcription factors that can regulate Ret expression, we found 
the Hypoxia Inducible Factor-1 (HIF-1) is the only transcription factor found to be 
associated with a down-regulation of Ret transcriptional level43. We then demonstrated that 
the post-transcriptional stabilization of HIF-1 is associated to a strong down-regulation of 
Ret protein level in human neuroblastoma cells. However, it’s not known the exact 
mechanism by which HIF-1 is able to regulate Ret expression. It will be interesting to 
analyze the mechanistic link and extend our knowledge of the functions of the hypoxia-
related pathways. 
 
Under normal oxygen conditions, HIF-1alpha (HIF-1a) subunit is hydroxylated at two 
proline residues within the oxygen-dependent degradation domain (ODDD) by prolyl-
hydroxylase-domain proteins (PHD), thereby targeting it for proteasomal degradation.  
Under hypoxic conditions, PHD are inhibited, thereby preventing hydroxylation of HIF-1a. 
Inhibiting PHD decreases degradation of HIF-1a by the ubiquitin-proteasome system and 
leads to rapid HIF-1a accumulation. HIF-1a translocates to the nucleus and dimerize with 
HIF-1b to initiate transcription of target genes.  
 
Interestingly, we have demonstrated that, in absence of DJ-1, the hypoxia-sensible subunit 
of HIF-1, HIF-1alpha, is strongly stabilized. 
Consequently, we investigated whether the absence of DJ-1 was responsible for the 
establishment of cellular hypoxia. Using hypoxyprobe, we have been able to demonstrate 
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for the first time that in absence of DJ-1, human neuroblastoma cells suffered of hypoxic 
condition. 
Although a role of DJ-1 in hypoxia cellular responses has been already postulated44, here 
we report for the first time the presence of a hypoxic condition generated by the absence of 
DJ-1 and not by exogenous stimuli.  
 
Oxygen availability regulates many physiological and patho-physiological processes, 
including embryonic development, adaptation to high altitudes, wound healing, and 
inflammation, as well as contibuting to the pathophysiology of cancer and ischemic 
diseases such as infarction and stroke 64. 
 
As a main consumer of energy, the brain is particularly susceptible to the effects of 
hypoxia 65. Mesotelencephalic dopamine (DA) pathways are exquisitely vulnerable to 
ischemic-anoxic insult. These insults are known to produce long-term derangements in DA 
signalling. However, it remains unclear whether modest intermittent hypoxia, such as that 
encountered with repetitive apnoeas in premature infants, contributes to clinically 
significant impairments in DA signalling 66. 
The physiological response to hypoxia includes vasodilatation of brain arteries and veins, 
which increases cerebral blood flow and delivery of oxygen to the brain. At molecular 
level, several pathways have recently been shown to mediate hypoxia sensing at the 
cellular and molecular levels 65. The induction of Hypoxia Inducible Factor-1 (HIF-1), and 
the consequent expression of HIF-1 target genes, is the key element of cellular response to 
hypoxia.  
Furthermore, oxidant stress increased under hypoxia and it can activate multiple signalling 
pathways including HIF-1alpha protein stabilization and gene regulation. Importantly, 
among genes regulated by HIF-1alpha there’s the rate-limiting enzyme for the synthesis of 
dopamine, tyrosine hydroxylase (TH). Whether the HIF/hypoxia responsiveness of TH 
might help in understanding the pathogenesis of Parkinson’s disease, or be useful in 
developing new therapies, is still unknown . 
 
Because of its link with oxidative stress, the role of DJ-1 was recently studied in other non-
PD-related neuropathological conditions also associated with ROS, such as stroke. It was 
found that DJ-1 provides protection against excitotoxicity and ischemic brain injury and 
that the anti-oxidant activity of DJ-1 is essential to its neuroprotective role against 
ischemia-induced damage. Indeed, it’s known strokes predispose patients to dementia 
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(Internal Medicine, 2003) and PD patients have symptoms not classically associated with 
movement such as dementia and mood disorders.  
 
We demonstrated an accumulation of free radical species in cells lacking DJ-1. 
Interestingly, this result confirmed what was observed by Andres-Mateos and colleagues in 
vivo in DJ-1 (-/-) mice. The lack of DJ-1 in the mitochondria induces an increase of 
mitochondrial H2O2 production and reduction of aconitase activity 54. Moreover, this result 
points out the essential role of DJ-1 in free radical scavenging. 
Importantly, we performed rescue experiment with both wild type and mutant DJ-1. We 
demonstrated that the re-introduction of fully functional DJ-1 was able to rescue Ret 
expression level. Conversely, Ret expression level was not rescued up neither by the 
transfection of DJ-1 PD related mutant (L166P), highly unstable, nor by DJ-1 mutant 
lacking of its scavenger activity (C106A). C106 residue for the anti-oxidant activity . 
Indeed, C106 is the most sensitive among all the three cystein residues (i.e. C46, C53 and 
C106) present in DJ-1 protein to oxidative stress 39. Indeed, the C106A mutation has been 
demonstrated to block oxidation-induced mitochondrial localization and protection against 
1-methyl-4-phenylpyridinium (MPP+) toxicity in neuronal cells 58.  
 
These results suggest that the restoring effects exerted by transfected DJ-1 could reside on 
its scavenger activity. Recent studies have demonstrated that DJ-1 could also be central to 
other models of neuronal injury where oxidative damage plays a paramount role like 
stroke. Aleyasin and colleagues have also demonstrated that DJ-1 deficiency sensitizes 
brains to ischemic damage in vivo and that the protective activity depends on cystein 106 
residue, shown to be critical in the DJ-1 ability to handle oxidative stress 58. 
 
Interestingly, after transfection of fully functional DJ-1 we observed also a reduction of 
HIF-1 alpha protein level implying the activation of the oxygen-sensible degradation 
pathway.  
To confirm this hypothesis we wanted to verify whether upon DJ-1 transfection the 
hypoxic condition was reduced. By immunofluorescence, we demonstrated the negative 
correlation existing for the hypoxic cells and cells transfected with DJ-1.  
 
These results demonstrate an involvement of DJ-1 in the oxygen signalling machinery. In 
this contest, it’s important to underline the role of mitochondria as integral members of 
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oxygen-sensing machinery. We could hypothesize that, other than the scavenger activity, 
DJ-1 could have a supporting role of mitochondrial activity in oxygen sensing. It’s known 
that DJ-1 but not the PD-mutants localize to mitochondria during oxidative stress. 
Furthermore, it has been demonstrated that resting mitochondrial membrane potential was 
significantly lower in DJ-1 (-/-) astrocytes, as compared to controls 56. 
 
Interestingly, accumulation of clonal, somatic mitochondrial DNA deletions has been 
observed in the SN during aging and in PD, suggesting that mitochondrial DNA mutations 
in some instances may pre-dispose to DA neuron death by impairing respiration 63.  
Several catalytic subunits of complex I were shown to carry increased levels of protein 
carbonyls (an oxidative modification of proteins) in the parkinsonian brain, which 
correlated with reduced electron transfer rates, suggesting that excessive oxidative damage 
of complex I subunits may lead to complex I misassembly and dysfunction 66. 
Interestingly, it appears that the SN is more vulnerable to impairments of complex I 
activity than other brain regions and peripheral organs, possibly due to the increased levels 
of reactive oxygen species generated within dopamine neurons as a result of dopamine 
metabolism and iron 64.  
Given the key role of mitochondria in neuronal function, it is not surprising that 
disturbances in mitochondrial function, transport, dynamics and turnover have emerged as 
central mechanisms at the convergence of neurotoxin, environmental and genetic 
approaches to Parkinson’s disease 
Taken together, these results suggest a new pathological mechanism underlying the DJ-1 
loss of function and PD onset. We demonstrated for the first time that lack of function of 
DJ-1 is responsible for the impairment in the oxygen sensing machinery and for an 
increase of free radical species. These phenomena may thus have strong implications in the 
GDNF neurotrophic signalling pathway and therefore could account for the 
neurodegeneration of dopaminergic neurons, a clear hallmark of PD.  
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5. MATERIALS AND METHODS 
 
5.1 Constructs 
Expression vectors encoding for FLAG-DJ-1 WT, C106A and pcDNA3-FLAG empty 
were previously described 106. Two different oligonucleotide sequences were selected for 
the knock-down DJ-1 expression using siRNA Target Finder software (Invitrogen). The 
hairpin-encoding oligonucleotides were cloned into the pSuperior vector (Invitrogen).  
siRNA constructs: siRNA#1 (5' - GGTCATTACACCTACTCTG - 3'), siRNA#2 (5' - 
TGGAGACGGTCATCCCTGT - 3'), scramble (5' - TGGAGACGGAGATCCCTGT - 3') 
 
5.2 Cell culture and transfections 
Human neuroblastoma SH-SY5Y cells (ATCC) were maintained in culture as suggested by 
vendors. SH-SY5Y cells were transfected with LipofectAmine 2000 (Invitrogen), 
according to manufacturer’s instructions. 
We generated SH-SY5Y inducible stable cell lines by transfecting linearized constructs 
with LipofectAmine 2000 and selecting for positive clones in the presence of 300 µg/ml of 
G418 (Invitrogen) and 3 µg/ml of Blasticidin (InvivoGen). Individual clones were 
confirmed by western blot analysis, immunofluorescence and quantitative real time PCR. 
Silencing induction was performed by adding 2.5 µg/ml of Doxycicline Hyclate (Sigma-
Aldrich) every 48h. 
 
5.3 DJ-1 KO mice 
Generation of DJ-1 (-/-) was previously described 84. mRNA from total ventral midbrain 
and striatum of  DJ-1-/-, DJ-1 WT and HZ 3 and 5 months old mice was collected and 
analyzed by qPCR. 
 
5.4 RNA isolation, reverse transcription and qPCR 
Total RNA was isolated using the TRIZOL reagent (Invitrogen) following the 
manufacturer’s instructions. Single strand cDNA was obtained from 1 µg of purified RNA 
using the iSCRIPTTM cDNA Synhesis Kit (Bio-Rad) according to manufacturer’s 
instructions. Quantitative RT-PCR (qPCR) was performed using SYBR-Green PCR 
Master Mix (Applied Biosystem) and an iCycler IQ Real time PCR System (Bio-Rad). 
Expression of DJ-1, RET, CDC42, GRM8, FLMNA, CAMK-IIb, and ITG-b1 was 
analyzed using specific oligonucleotides (supplementary material). 
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5.5 Microarray processing and data analysis 
Total RNA was extracted as described above and purified using the RNeasy mini kit 
(Qiagen). The quality of total RNA was assessed using a bioanalyzer (Agilent 2100; 
Agilent Technologies) and RNA was quantified by using a ND-1000 Nanodrop 
spectrophotometer. 10 µg of each total RNA sample was labelled according to the standard 
one-cycle amplification and labelling protocol developed by Affymetrix (Santa Clara, CA). 
Labelled cRNA was hybridized on Affymetrix GeneChip Human U133A 2.0 Arrays 
containing over 14,500 transcripts. Hybridized GeneChips were stained, washed 
(GeneChip Fluidic Station 450) and scanned (GeneChip Scanner 3000 7G). Cell intensity 
values and probe detection calls were computed from the raw array data using the 
Affymetrix GeneChip Operating Software (GCOS). Further data processing was 
performed in the R computing environment using packages from the BioConductor 
software project (http://www.bioconductor.org/). Robust Multi-Array Average (RMA) 
normalization was applied 157. Normalized data were then filtered based on the Affymetrix 
detection call, so that only probes that had a Present call in at least one of the arrays were 
retained. Data were then imported in the MultiExperiment Viewer (MeV) software 158, and 
statistical analysis was performed with the SAM (Significance Analysis of Microarrays) 
module 159 to detect significantly differentially expressed genes. Microarray data have been 
deposited in the NCBI Gene Expression Omnibus (GEO) with Accession Number 
GSE17204. Differentially expressed genes were then specifically examined, based on their 
Gene Ontology annotation 160 and through the use of Ingenuity Pathways Analysis 
(Ingenuity Systems®, www.ingenuity.com) and DAVID Bioinformatics Resources 161. 
 
5.6 Western blot analysis 
Cells were lysed in 2X SDS sample buffer, boiled and analyzed by western blot. Proteins 
were then separated by molecular weight by SDS/PAGE through polyacrilamide gels 
ranging from 8% to 10%.  Proteins were electrophoretically transferred to nitrocellulose 
membranes and blocked using 5% nonfat dry milk in TBS with 0.1% Tween 20. 
The following antibodies were used: anti-DJ-1 1:1000 (purified from immunized rabbits) 
and anti-DJ-1 1:1000 (Stressgene), anti-Flag 1:2000 (Sigma), anti-Ret 1:400 (SantaCruz), 
anti-Hif-1a 1:400 (SantaCruz), anti-β-actin 1:5000 (Sigma). 
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5.7 Immunocytochemistry and immunohistochemistry 
For immunofluorescence experiments, SH-SY5Y cells were fixed in 4% paraformaldehyde 
and indirect immunofluorescence was performed following standard protocols 
(supplementary material).  We used a anti-DJ-1 1:100 (purified from immunized rabbits) 
and anti-DJ-1 1:100 (Stressgene), Anti-HypoxyprobeTM-1 antibody (Chemicon 
International Corp.), anti-Flag 1:1000 (Sigma) For detection, Alexa Fluor-488 or -594 
(Invitrogen) labeled anti-mouse or anti-rabbit antibodies were used. Nuclei were visualized 
with DAPI  (1mg/ml). All images were collected using a confocal microscope (LEICA 
TCS SP2). 
 
5.8 ROS measurements 
Dihydroethidium (DHE) is a specific dye for O2·- detection. The blue fluorescent dye HE 
is oxidized by O2·- to ethidium, which stains the nucleus a bright fluorescent red. SH-
SY5Y cells (4×105 cells/60-mm Petri dishes) were rinsed and 10 mM DHE was loaded. 
After 20-min incubation at 37 °C in serum-free medium, cells were examined under a 
confocal microscope. 
 
5.9 Colocalization analysis 
Scatter Plot and Pearson’s Coefficient of colocalization have been obtained with ImageJ 
software from 10 different fields each experiment. All experiment have been performed in 
triplicate and in two different clones. 
 
5.10 Statistical analysis 
All experiments were repeated in triplicate or more. For stably transfected cells, at least 
two independent clones were used for each cell line in all experiments. Data represent the 
mean ±SEM. When necessary, each group was compared individually with reference 
control group using Student’s t-test (Microsoft Excel software). 
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SUPPLEMENTARY 
 
gene_name gene_symbol FC 
NEL-like 1 (chicken) NELL1 5.00 
cell division cycle 42 (GTP binding protein, 25kDa) CDC42 4.40 
calcium/calmodulin-dependent protein kinase (CaM kinase) II beta CAMK2B 4.05 
transmembrane protein 16C TMEM16C 4.03 
glutamate receptor, metabotropic 8 GRM8 3.91 
latrophilin 3 LPHN3 3.84 
stathmin-like 4 STMN4 3.50 
AP2 associated kinase 1 AAK1 3.49 
v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) ERBB4 3.44 
GNAS complex locus GNAS 3.24 
jun oncogene JUN 3.15 
zinc finger protein 804A ZNF804A 3.09 
sparc/osteonectin, cwcv and kazal-like domains proteoglycan 
(testican) 3 SPOCK3 3.07 
polypyrimidine tract binding protein 2 PTBP2 2.95 
sorbin and SH3 domain containing 2 SORBS2 2.92 
solute carrier family 7, (cationic amino acid transporter, y+ system) 
member 11 SLC7A11 2.92 
nucleosome assembly protein 1-like 3 NAP1L3 2.87 
jumonji domain containing 6 JMJD6 2.83 
roundabout, axon guidance receptor, homolog 2 (Drosophila) ROBO2 2.77 
achaete-scute complex homolog 1 (Drosophila) ASCL1 2.71 
basic helix-loop-helix domain containing, class B, 2 BHLHB2 2.66 
plexin C1 PLXNC1 2.62 
RUN and FYVE domain containing 3 RUFY3 2.62 
dehydrogenase/reductase (SDR family) member 2 DHRS2 2.59 
ATP-binding cassette, sub-family A (ABC1), member 12 ABCA12 2.58 
fibronectin leucine rich transmembrane protein 3 FLRT3 2.58 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 5 ST6GALNAC5 2.54 
DKFZP564C152 protein DKFZP564C152 2.49 
plakophilin 4 PKP4 2.44 
tripartite motif-containing 29 TRIM29 2.42 
histone cluster 1, H2bg HIST1H2BG 2.42 
potassium voltage-gated channel, Shab-related subfamily, member 1 KCNB1 2.41 
receptor accessory protein 1 REEP1 2.32 
synaptotagmin XVII SYT17 2.31 
regulator of chromosome condensation (RCC1) and BTB (POZ) 
domain containing protein 2 RCBTB2 2.28 
brain-specific angiogenesis inhibitor 3 BAI3 2.24 
metastasis suppressor 1 MTSS1 2.21 
ankyrin 2, neuronal ANK2 2.20 
ADP-ribosylation factor-like 4C ARL4C 2.20 
neuropilin 1 NRP1 2.19 
regulator of G-protein signalling 4 RGS4 2.19 
PDZ and LIM domain 3 PDLIM3 2.18 
histone cluster 2, H2be HIST2H2BE 2.17 
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog KIT 2.16 
phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) PIK3R1 2.16 
diacylglycerol kinase, iota DGKI 2.15 
eyes absent homolog 1 (Drosophila) EYA1 2.13 
leucine rich repeat neuronal 3 LRRN3 2.12 
solute carrier family 1 (glutamate/neutral amino acid transporter), 
member 4 SLC1A4 2.11 
solute carrier family 18 (vesicular monoamine), member 2 SLC18A2 2.11 
glutamate receptor, ionotropic, AMPA 2 GRIA2 2.09 
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guanine nucleotide binding protein (G protein), alpha activating 
activity polypeptide O GNAO1 2.08 
p21 (CDKN1A)-activated kinase 3 PAK3 2.08 
histone cluster 1, H2ag HIST1H2AG 2.07 
regulator of G-protein signalling 7 RGS7 2.06 
40S ribosomal protein S20 pseudogene LOC440992 2.06 
PDZ and LIM domain 7 (enigma) PDLIM7 2.05 
endothelial PAS domain protein 1 EPAS1 2.05 
solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 5 SLC7A5 2.03 
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2 B3GALT2 2.02 
tropomyosin 1 (alpha) TPM1 2.01 
mitofusin 1 MFN1 0.50 
chromosome 4 open reading frame 31 C4orf31 0.50 
ADAM metallopeptidase domain 12 (meltrin alpha) ADAM12 0.50 
calcium binding and coiled-coil domain 2 CALCOCO2 0.50 
related RAS viral (r-ras) oncogene homolog RRAS 0.49 
SH3 domain and tetratricopeptide repeats 1 SH3TC1 0.49 
NAD(P)H dehydrogenase, quinone 1 NQO1 0.49 
frizzled homolog 7 (Drosophila) FZD7 0.49 
odz, odd Oz/ten-m homolog 4 (Drosophila) ODZ4 0.49 
ATPase, Cu++ transporting, alpha polypeptide (Menkes syndrome) ATP7A 0.49 
SNF1-like kinase 2 SNF1LK2 0.48 
pre-B-cell leukemia homeobox 1 PBX1 0.48 
glutaredoxin (thioltransferase) GLRX 0.48 
carbohydrate (chondroitin 4) sulfotransferase 11 CHST11 0.48 
low density lipoprotein receptor-related protein 10 LRP10 0.48 
interferon-induced protein 44 IFI44 0.48 
annexin A2 pseudogene 2 ANXA2P2 0.48 
peroxidasin homolog (Drosophila) PXDN 0.47 
arylsulfatase family, member J ARSJ 0.47 
actin, alpha 2, smooth muscle, aorta ACTA2 0.47 
G protein-coupled receptor 177 GPR177 0.47 
neurogenin 2 NEUROG2 0.47 
SMAD family member 3 SMAD3 0.46 
chromosome 20 open reading frame 103 C20orf103 0.46 
sprouty homolog 2 (Drosophila) SPRY2 0.46 
vimentin VIM 0.46 
pleckstrin and Sec7 domain containing 3 PSD3 0.45 
Niemann-Pick disease, type C2 NPC2 0.45 
integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 
includes MDF2, MSK12) ITGB1 0.45 
lectin, galactoside-binding, soluble, 3 LGALS3 0.44 
annexin A2 ANXA2 0.43 
collagen, type IV, alpha 1 COL4A1 0.43 
phosphorylase, glycogen; liver (Hers disease, glycogen storage 
disease type VI) PYGL 0.43 
guanine nucleotide binding protein (G protein), gamma 11 GNG11 0.43 
H2A histone family, member Y H2AFY 0.42 
guanine nucleotide binding protein (G protein), gamma 12 GNG12 0.41 
septin 6 SEPT6 0.41 
AHNAK nucleoprotein (desmoyokin) AHNAK 0.41 
PTPRF interacting protein, binding protein 1 (liprin beta 1) PPFIBP1 0.41 
BCL2-associated athanogene 3 BAG3 0.41 
NADPH oxidase 3 NOX3 0.40 
NAD(P)H dehydrogenase, quinone 1 NQO1 0.40 
nidogen 1 NID1 0.40 
transcription factor 7-like 2 (T-cell specific, HMG-box) TCF7L2 0.40 
limb bud and heart development homolog (mouse) LBH 0.40 
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integrin, beta 5 ITGB5 0.39 
PDZ and LIM domain 5 PDLIM5 0.39 
low density lipoprotein receptor-related protein 4 LRP4 0.39 
major histocompatibility complex, class I, C HLA-C 0.39 
target of myb1 (chicken)-like 1 TOM1L1 0.38 
dermatopontin DPT 0.38 
platelet-derived growth factor receptor, alpha polypeptide PDGFRA 0.37 
catenin (cadherin-associated protein), delta 1 CTNND1 0.37 
chromosome 10 open reading frame 56 C10orf56 0.37 
heparan sulfate (glucosamine) 3-O-sulfotransferase 2 HS3ST2 0.36 
cytokine-like 1 CYTL1 0.36 
leucine-rich repeat-containing G protein-coupled receptor 5 LGR5 0.35 
tensin 1 TNS1 0.35 
glutamate receptor, metabotropic 7 GRM7 0.35 
brain and acute leukemia, cytoplasmic BAALC 0.33 
filamin A, alpha (actin binding protein 280) FLNA 0.33 
inhibitor of DNA binding 4, dominant negative helix-loop-helix protein ID4 0.33 
cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMP-
N-acetylneuraminate monooxygenase) CMAH 0.32 
cadherin 11, type 2, OB-cadherin (osteoblast) CDH11 0.32 
neuron navigator 2 NAV2 0.32 
peptidylprolyl isomerase C (cyclophilin C) PPIC 0.32 
G protein-coupled receptor 37 (endothelin receptor type B-like) GPR37 0.31 
plasminogen activator, tissue PLAT 0.30 
protease, serine, 12 (neurotrypsin, motopsin) PRSS12 0.30 
family with sequence similarity 59, member A FAM59A 0.30 
synaptosomal-associated protein, 23kDa SNAP23 0.30 
5-hydroxytryptamine (serotonin) receptor 2B HTR2B 0.29 
sushi-repeat-containing protein, X-linked SRPX 0.29 
Notch homolog 2 (Drosophila) NOTCH2 0.29 
neuropeptide Y NPY 0.28 
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention 
receptor 3 KDELR3 0.28 
WD repeat domain, phosphoinositide interacting 1 WIPI1 0.28 
ret proto-oncogene RET 0.28 
tensin 3 TNS3 0.27 
sparc/osteonectin, cwcv and kazal-like domains proteoglycan 
(testican) 1 SPOCK1 0.27 
PTPRF interacting protein, binding protein 2 (liprin beta 2) PPFIBP2 0.24 
trophoblast glycoprotein TPBG 0.24 
popeye domain containing 2 POPDC2 0.23 
pleiomorphic adenoma gene-like 1 PLAGL1 0.23 
glutamate decarboxylase 1 (brain, 67kDa) GAD1 0.22 
collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, 
autosomal dominant) COL3A1 0.21 
dihydropyrimidinase-like 3 DPYSL3 0.21 
complement component 7 C7 0.20 
integral membrane protein 2A ITM2A 0.20 
sprouty homolog 1, antagonist of FGF signaling (Drosophila) SPRY1 0.19 
sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3C SEMA3C 0.19 
pleiotrophin (heparin binding growth factor 8, neurite growth-
promoting factor 1) PTN 0.19 
reelin RELN 0.16 
tissue factor pathway inhibitor 2 TFPI2 0.15 
Parkinson disease (autosomal recessive, early onset) 7 PARK7 0.13 
regulator of G-protein signalling 13 RGS13 0.10 
versican VCAN 0.08 
dickkopf homolog 2 (Xenopus laevis) DKK2 0.04 
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qPCR SPECIFIC OLIGONUCLEOTIDES 
 
Human DJ-1 
 
Fwd 
5’- GAGACGGTCATCCCTGTAG – 3’ 
Rev 
5’- CATCTTCAAGGCTGGCATC – 3’ 
 
Human Grm8 
 
Fwd 
5’ – GACCCTGATCTCCTTTCCAACATC – 3’ 
Rev 
5’ – TCTCCATTAGCACACTTCACATCC – 3’ 
 
Human CAMKIIb 
 
Fwd 
5’ – ACTCAACAAGAAAGCAGATG – 3’ 
Rev 
5’ – ATCCTCTATGGTGGTATTGG – 3’ 
 
Human CDC42 
 
Fwd 
5’ – GCACTTACACAGAGAGGTC – 3’ 
Rev 
5’ – AGTAGTGGGACAGGAAGC – 3’ 
 
Human FLMNA 
 
Fwd 
5’ – GACGGCTCCTGTGATGTG – 3’ 
Rev 
5’ – TCTGCTGGCTTGTTGACG – 3’ 
 
Human RET 
 
Fwd 
5’ – GCCACCGACCAGCAGACC – 3’ 
Rev 
5’ – CGCCACACTCCTCACACTCC – 3’ 
 
Mouse RET 
 
Fwd 
5’- GGCACCTTCTACCACTTCC – 3’ 
Rev 
5’- CCTCCAGCACATACTTCTCC – 3’ 
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HOUSEKEEPING GENES 
 
Human β-Actin 
 
Fwd 
5’ – CGCCGCCAGCTCACCATG – 3’ 
Rev 
5’ – CACGATGGAGGGGAAGACGG – 3’ 
 
Human GAPDH 
 
Fwd 
5’ – TCTCTGCTCCTCCTGTTC – 3’ 
Rev 
5’ – GCCCAATACGACCAAATCC – 3’ 
 
Mouse β-Actin 
 
Fwd 
5’ – CCTTCTTGGGTATGGAATCCTGTG – 3’ 
Rev 
5’ – CAGCACTGTGTTGGCATAGAGG – 3’ 
 
Mouse GAPDH 
 
Fwd 
5’ – GCAGTGGCAAAGTGGAGATT – 3’ 
Rev 
5’ – GCAGAAGGGGCGGAGATGAT – 3’ 
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